[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 331
1. Singer M, Mutch MG: Anal melanoma. Clin Colon Rectal Surg; 2006 May;19(2):78-87
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal melanoma.
  • Anal melanoma is rare and aggressive malignancy.
  • Patients commonly present with advanced, even metastatic disease.
  • Unlike cutaneous melanoma, anal melanoma has no known risk factors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1341-8 [10219070.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5 [10522715.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Oncology (Williston Park). 1999 Nov;13(11):1561-74; discussion 1574 passim [10581603.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):863-7 [10741708.001]
  • [Cites] Recent Results Cancer Res. 2000;157:178-89 [10857171.001]
  • [Cites] Curr Oncol Rep. 2000 Jul;2(4):292-9 [11122856.001]
  • [Cites] Chir Ital. 2000 Jul-Aug;52(4):329-34 [11190522.001]
  • [Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]
  • [Cites] Tech Coloproctol. 2001 Apr;5(1):51-4 [11793262.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72 [11958890.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9 [12368672.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1545-8 [12397731.001]
  • [Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):53-6 [12630771.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]
  • [Cites] Anticancer Drugs. 2005 Mar;16(3):345-8 [15711188.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Int Surg. 1980 Sep-Oct;65(5):423-6 [7451062.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3 [7473820.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:167-77 [8368735.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):81-6 [8409692.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Histopathology. 1993 Mar;22(3):261-4 [8495957.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):88-94 [10618610.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):87-97 [10761786.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):680-4 [11034246.001]
  • [Cites] Surg Today. 2001;31(6):527-9 [11428607.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):53-9 [11719029.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • [Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Radiother Oncol. 1989 Nov;16(3):169-82 [2587808.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Acta Chir Scand. 1974;140(1):68-72 [4819025.001]
  • [Cites] CA Cancer J Clin. 1966 May-Jun;16(3):111-4 [4957071.001]
  • [Cites] Dis Colon Rectum. 1967 May-Jun;10(3):161-76 [6026797.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]
  • [Cites] Am J Surg. 1983 Sep;146(3):336-8 [6614323.001]
  • [Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Dis Colon Rectum. 1980 Mar;23(2):122-4 [7379659.001]
  • [Cites] Arch Surg. 1996 Sep;131(9):975-9; 979-80 [8790168.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Mar;16(1):81-5 [9148866.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Surg Today. 1997;27(8):753-6 [9306593.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9 [9660028.001]
  • [Cites] Eur J Surg Oncol. 1998 Aug;24(4):303-7 [9724998.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S22-6 [9849405.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):476-80 [9887254.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • (PMID = 20011314.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780102
  • [Keywords] NOTNLM ; Melanoma / abdominoperineal resection / anal / malignancy / wide local excision
  •  go-up   go-down


2. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • Fourteen percent of T1 patients (3 out of 22), 42% of T2 patients (10 out of 24) and 40% of T3-4 patients (6 out of 15) assessed using CIm, had a change in their nodal or metastatic stage following FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


3. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • Six months before her admission to our hospital, anal pain developed.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • Histopathological examination revealed no remnant cancer tissue or lymph node metastasis.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Two years later, the patient died of metastatic urinary bladder cancer, without recurrence of the fistula cancer.
  • Because the patients mother had died of urinary bladder cancer and she herself had metachronous urinary bladder cancer in addition to fistula cancer, we investigated whether microsatellite instability (MSI) and chromosomal instability correlated with fistula cancer development.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G: Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res; 2010 Sep 01;70(17):6815-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
  • Current treatment for late-stage metastatic breast cancer is largely palliative. alpha-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus.
  • Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated.

  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):706-15 [15665617.001]
  • [Cites] Health Phys. 1960 Feb;2:225-38 [13818815.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Curr Pharm Des. 2006;12(36):4729-49 [17168775.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7 [17935286.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Feb;5(2):189-204 [18248318.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):74-81 [18298331.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3873-80 [18483272.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8941-8 [19920193.001]
  • [Cites] J Nucl Med. 2010 Feb;51(2):311-28 [20080889.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1935-46 [10565792.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3569-76 [10910070.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):253-60 [14960644.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3765-70 [8339289.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107 [8110825.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3352-6 [8012948.001]
  • [Cites] Nucl Med Biol. 1995 Apr;22(3):387-90 [7627155.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1639-44 [7658225.001]
  • [Cites] J Leukoc Biol. 1996 Sep;60(3):337-44 [8830790.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):489-93 [9074545.001]
  • [Cites] Appl Radiat Isot. 1999 May;50(5):895-904 [10214708.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):87-95 [10528086.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):466-8 [13641241.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6288-91 [16194090.001]
  • (PMID = 20651254.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113797; United States / NCI NIH HHS / CA / R01 CA113797-04; United States / NCI NIH HHS / CA / R01 CA187037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Isothiocyanates; 0 / Liposomes; 0 / Radioisotopes; 142434-84-2 / N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; 7A314HQM0I / Pentetic Acid; EC 2.7.10.1 / Receptor, ErbB-2; U015TT5I8H / Bismuth
  • [Other-IDs] NLM/ NIHMS248891; NLM/ PMC2977986
  •  go-up   go-down


5. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


6. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park); 2010 Apr 15;24(4):364-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
  • Although anal cancer is a rare disease, its incidence is increasing in men and women worldwide.
  • Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
  • Meta-analysis suggests that 80% of anal cancers could be avoided by vaccination against HPV 16/18.
  • Nearly half of all patients with anal cancer present with rectal bleeding.
  • According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with anal cancer have disease localized to the anus, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
  • Clinical staging of anal carcinoma requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
  • The 5-year relative survival rates are 80.1% for localized anal cancer, 60.7% for regional disease, and 29.4% for metastatic disease.
  • Part 2 of this two-part review will address the treatment of anal cancer, highlighting studies of chemoradiation.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Mass Screening

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464850.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


7. Sahai A, Kodner IJ: Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg; 2006 May;19(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.
  • Premalignant and malignant lesions of the anal margin are rare.
  • Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.
  • Combined multimodality treatment has come to play an important role in managing patient with more advanced or metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]
  • [Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]
  • [Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]
  • (PMID = 20011315.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780101
  • [Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer
  •  go-up   go-down


8. Xu HN, Nioka S, Glickson JD, Chance B, Li LZ: Quantitative mitochondrial redox imaging of breast cancer metastatic potential. J Biomed Opt; 2010 May-Jun;15(3):036010
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative mitochondrial redox imaging of breast cancer metastatic potential.
  • Predicting tumor metastatic potential remains a challenge in cancer research and clinical practice.
  • Our goal was to identify novel biomarkers for differentiating human breast tumors with different metastatic potentials by imaging the in vivo mitochondrial redox states of tumor tissues.
  • The more metastatic (aggressive) MDA-MB-231 and less metastatic (indolent) MCF-7 human breast cancer mouse xenografts were imaged with the low-temperature redox scanner to obtain multi-slice fluorescence images of reduced nicotinamide adenine dinucleotide (NADH) and oxidized flavoproteins (Fp).
  • Mitochondrial redox imaging can be clinically implemented utilizing cryogenic biopsy specimens and is useful for drug development and for clinical diagnosis of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1968 Jun 28;31(6):895-900 [4299232.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • [Cites] J Biol Chem. 1979 Jun 10;254(11):4764-71 [220260.001]
  • [Cites] J Biol Chem. 1982 May 25;257(10):5476-81 [7068601.001]
  • [Cites] Science. 1982 Sep 10;217(4564):998-1003 [7112116.001]
  • [Cites] J Natl Cancer Inst. 1984 Apr;72(4):913-7 [6584666.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2259-65 [6372991.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5702-6 [6498833.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4716-22 [11406542.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):309-15 [11988105.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Bioconjug Chem. 2003 Jul-Aug;14(4):709-14 [12862422.001]
  • [Cites] Nucl Med Biol. 2004 Aug;31(6):761-70 [15246367.001]
  • [Cites] J Biomed Opt. 2004 Jul-Aug;9(4):772-8 [15250765.001]
  • [Cites] Science. 2008 May 2;320(5876):661-4 [18388260.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:96S-112S [18523068.001]
  • [Cites] Mitochondrion. 2008 Sep;8(4):339-44 [18727959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1298-306 [19028270.001]
  • [Cites] Adv Exp Med Biol. 2009;645:247-53 [19227478.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2588-93 [19351761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6608-13 [19366661.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Science. 1952 Aug 22;116(3008):200-2 [17792313.001]
  • [Cites] Anal Biochem. 1985 Aug 1;148(2):389-400 [4061818.001]
  • [Cites] Adv Exp Med Biol. 1973;37A:277-92 [4378058.001]
  • [Cites] Biotechniques. 1990 Sep;9(3):324-31 [2223075.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 5;84(3):165-74 [1371813.001]
  • [Cites] FASEB J. 1995 May;9(8):651-8 [7768357.001]
  • [Cites] Clin Exp Metastasis. 1997 Jan;15(1):53-62 [9009106.001]
  • [Cites] Nat Med. 1997 Feb;3(2):177-82 [9018236.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int Rev Cytol. 1998;177:1-56 [9378615.001]
  • [Cites] Ann N Y Acad Sci. 1997 Dec 29;833:137-46 [9616746.001]
  • [Cites] Mutat Res. 1998 Feb 26;398(1-2):19-26 [9626961.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Nature. 1955 Aug 6;176(4475):250-4 [13244669.001]
  • [Cites] J Biol Chem. 1958 Sep;233(3):736-9 [13575447.001]
  • [Cites] Science. 1959 Mar 13;129(3350):700-8 [13635004.001]
  • [Cites] Science. 1962 Aug 17;137(3529):499-508 [13878016.001]
  • [Cites] J Biol Chem. 1955 Nov;217(1):429-38 [13271405.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23(8):1664-73 [15755974.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):125-6 [15725722.001]
  • [Cites] J Control Release. 2005 Dec 5;109(1-3):222-35 [16290245.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] J Fluoresc. 2007 Jan;17(1):37-42 [17171438.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36 [16971499.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Neoplasia. 2007 May;9(5):382-91 [17534443.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1221-35 [17536958.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):267-74 [17551814.001]
  • [Cites] Circ Res. 1976 May;38(5 Suppl 1):I31-8 [178460.001]
  • (PMID = 20615012.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA083105; United States / NCI NIH HHS / CA / U01 CA105490; United States / NCRR NIH HHS / RR / RR02305; United States / NCI NIH HHS / CA / UO1-CA105490; United States / NCI NIH HHS / CA / U54 CA105008; United States / NCRR NIH HHS / RR / P41 RR002305; United States / NCI NIH HHS / CA / 2U24-CA083105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Flavoproteins; 0U46U6E8UK / NAD
  • [Other-IDs] NLM/ PMC3188620
  •  go-up   go-down


9. Moreau MV, Tournier-Rangeard L, Kaminsky MC, Peiffert D: [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer]. Cancer Radiother; 2009 Jul;13(4):329-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer].
  • [Transliterated title] Chimioradiothérapie de rattrapage pour métastases médiastinales et pleuropulmonaires d'un cancer du canal anal.
  • This case report presents a 57 years-old woman treated for a squamous cell carcinoma of the anal canal by radiochemotherapy and brachytherapy.
  • The particularity of this case lays on the fact that she presented a mediastinal and pleural metastatic evolution three years later, which was also treated by radiochemotherapy, leading to a complete remission of 50 months.
  • This observation is interesting for its curative treatment in metastatic cancer of the anal canal.
  • It also illustrates the radiosensibility of anal canal cancers, including metastatic situations, and raises the contribution of PET-scanner to evaluate the response to treatment and detect a recurrence.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell / secondary. Mediastinal Neoplasms / secondary. Pleural Neoplasms / secondary. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467897.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Eng C, Pathak P: Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol; 2008 Dec;9(4-6):400-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options in metastatic squamous cell carcinoma of the anal canal.
  • Squamous cell carcinoma of the anal canal is a rare malignancy that is often cured with the combined modality therapy of chemoradiation.
  • Yet, a minority of patients will develop distant metastatic disease, an area of oncology in which a universally accepted approach has not been determined.
  • Consideration of platinum-based systemic chemotherapy is commonly provided for palliation with the optimal duration of therapy being largely unknown; the role of biologics and/or surgical resection of metastatic disease are anecdotal.
  • Here, we present a summary of the existing literature in the treatment of metastatic anal carcinoma in the hopes of providing insight and potential treatment alternatives for the practicing physician.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479383.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology; 2009;77(5):293-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
  • BACKGROUND: No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors.
  • Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far.
  • METHODS: We report on 7 patients with metastatic anal cancer treated with cetuximab - a chimeric antibody against EGFR - on a compassionate use basis along with the results of KRAS mutational analysis.
  • CONCLUSION: Cetuximab-based treatment appears to be a valuable treatment option for patients with metastatic KRAS wild-type anal cancer after failure of or as an alternative to cisplatin/5-fluorouracil-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. ras Proteins / genetics
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Compassionate Use Trials. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19923868.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  •  go-up   go-down


12. Haberstich R, Tuech JJ, Wilt M, Rodier JF: Anal localization as first manifestation of metastatic ductal breast carcinoma. Tech Coloproctol; 2005 Dec;9(3):237-8
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal localization as first manifestation of metastatic ductal breast carcinoma.
  • The incidence of extrahepatic gastrointestinal metastases from breast cancer is reported in the literature only as necroscopy studies (6-18%); they usually originate from lobular or a mixed ductal-lobular subtype.
  • We report here a case of rectal metastasis from an invasive ductal carcinoma (IDC).
  • This is to our knowledge, the first recorded instance of an anal metastasis from IDC.
  • [MeSH-major] Anus Neoplasms / secondary. Anus Neoplasms / therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Nitriles / administration & dosage. Triazoles / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328121.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


13. Jhawer M, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, Haller D: Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Invest New Drugs; 2006 Sep;24(5):447-54
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282.
  • Metastatic anal cancer is a rare disease in the Western hemisphere and current treatment modalities are not effective.
  • In this study, patients with advanced epithelial cancer of the anal canal received MAP followed by Bleomycin and CCNU upon progression of disease.
  • The combination therapy of MAP followed by Bleomycin and CCNU for patients with advanced anal cancer, not amenable to radiotherapy or surgery, results in a moderate objective response but with moderate toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763788.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 66636; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA14958; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA25988
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 50SG953SK6 / Mitomycin; 7BRF0Z81KG / Lomustine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Sato H, Koh PK, Bartolo DC: Management of anal canal cancer. Dis Colon Rectum; 2005 Jun;48(6):1301-15
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal canal cancer.
  • PURPOSE: Chemoradiotherapy has replaced radical surgery as the initial treatment of choice for anal canal cancer.
  • The roles of these therapeutic modalities are discussed and recommendations on management of anal canal cancer are made based on currently available evidence.
  • METHODS: Literature on management of anal canal cancer from January 1970 to July 2003 obtained via MEDLINE was reviewed.
  • Reports on anal margin cancers were excluded.
  • RESULTS: Randomized, prospective, Phase 3 trials in Europe and the United States showed that chemoradiotherapy with 5-fluorouracil and mitomycin C was superior in local control, colostomy-free rate, progression-free survival, and cancer-specific survival compared with radiation alone.
  • Few studies addressed the treatment of metastatic disease, which remains a major cause of mortality.
  • [MeSH-major] Anus Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793642.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 116
  •  go-up   go-down


15. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Metastatic disease spread to lymph nodes, viscera and bone was recorded.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).
  • Long-term results on survival and metastatic spread have to be awaited.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cummings BJ: Current management of anal canal cancer. Semin Oncol; 2005 Dec;32(6 Suppl 9):S123-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of anal canal cancer.
  • Combined-modality therapy consisting of radiation therapy and 5-fluorouracil plus mitomycin remains the standard treatment for localized anal canal cancer, permitting preservation of organ function and achieving high response and survival rates.
  • Metastatic disease is less responsive to chemoradiation treatment.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399449.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


19. Tomimaru Y, Ohue M, Noura S, Tanida T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1776-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer].
  • A 63-year-old man with a history of anal fistula was admitted to our hospital because the anal pain didn't disappear after the operation.
  • On digital examination, a hard mass measuring 3.0 cm in diameter was found at the anal canal.
  • Colonoscopy revealed another rectal cancer at 15 cm from anal verge.
  • Biopsy of the tumor also showed moderately differentiated adenocarcinoma, resembling the anal canal tumor.
  • Because the histological findings of both tumors were nearly identical, we considered that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal fistula.
  • The patient underwent anterior resection for the rectal cancer, and a local resection for the anal canal cancer.
  • We may suggest from these results that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / complications. Rectal Neoplasms / pathology


20. Fayaz S, Vasishta S, Motawy M: Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy. Gulf J Oncolog; 2007 Jul;(2):65-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy.
  • A fifty-two years old Egyptian lady, case of cloacogenic carcinoma of anal canal with extensive liver metastasis showed complete remission with 5-Fluorouracil (5FU) and Cis-Dichlorodiammineplatinum(CDDP) chemotherapy only and remains disease free five & haf years after therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Liver Neoplasms / drug therapy. Survivors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084726.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kuwait
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Damin DC, Tolfo GC, Rosito MA, Spiro BL, Kliemann LM: Sentinel lymph node in patients with rectal cancer invading the anal canal. Tech Coloproctol; 2010 Jun;14(2):133-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node in patients with rectal cancer invading the anal canal.
  • BACKGROUND: To assess the feasibility of the sentinel lymph node procedure in patients with rectal cancer extending to the anal canal.
  • METHODS: Between January 2005 and April 2008, 15 patients with adenocarcinoma of the rectum with direct invasion of the anal canal and no clinical evidence of inguinal involvement were prospectively enrolled in the study.
  • Four patients (26.7%) had sentinel nodes identified as positive for metastatic adenocarcinoma.
  • Of the 11 patients with negative sentinel nodes, only four (36.4%) also presented metastatic perirectal lymph nodes.
  • CONCLUSIONS: The standardized procedure was highly effective in sampling inguinal sentinel nodes in very low rectal cancers, allowing the detection of subclinical metastatic disease.
  • Although this technique can be potentially useful for a subgroup of patients with isolated inguinal metastases, it cannot be routinely recommended for patients with rectal tumors invading the anal canal at this moment.
  • [MeSH-major] Adenocarcinoma / secondary. Anal Canal. Inguinal Canal. Rectal Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424879.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • Four patients died with metastatic disease, 1 is alive with pelvic recurrence at 55 months, and 1 is alive without evidence of disease at 19 months follow-up.
  • Mean delay of cancer diagnosis was 11 months.
  • Periodical cancer surveillance should be performed in all patients with long-standing perianal CD fistulae.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology


23. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • Four patients relapsed and all were salvaged with surgery; two for local disease requiring abdominoperineal resection, one with an inguinal nodal relapse requiring inguinofemoral block dissection and one for metastatic disease to the liver who underwent liver resection.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal Canal. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, Li S, McCollum N, Ferrara A, Gallagher JT, Baker CH: Novel murine model for colon cancer: non-operative trans-anal rectal injection. J Surg Res; 2009 Jun 15;154(2):299-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel murine model for colon cancer: non-operative trans-anal rectal injection.
  • BACKGROUND: This study was conducted to develop a modified murine model of colon cancer that is non-operative.
  • Currently, the most accurate orthotopic murine model of colon cancer requires an invasive procedure involving cecal injection of colon cancer cells and therefore limits the ability to perform immunological studies subsequent to cecal resections.
  • MATERIALS AND METHODS: Murine colon cancer (CT26) cells were injected submucosally into the distal, posterior rectum of BALB/c mice.
  • Different magnifications (10x versus 100x) were used for injection, and primary tumor growth and metastatic disease were studied.
  • The overall success of tumor take was 65% using the trans-anal rectal injection model.
  • CONCLUSIONS: Our modified orthotopic murine model of colon cancer offers an alternative non-operative murine model for colon cancer and is less invasive than the traditional orthotopic model (i.e., cecal injection).
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Disease Models, Animal. Mice, Inbred BALB C. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Differentiation. Cell Line, Tumor. Injections / methods. Lung / pathology. Lung Neoplasms / secondary. Mice. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101690.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Al-Sukhni W, McLeod RS, MacRae H, O'Connor B, Huang H, Cohen Z: Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. Dis Colon Rectum; 2010 Nov;53(11):1495-500
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis.
  • PURPOSE: Ulcerative colitis is a risk factor for colorectal cancer.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis is a standard surgical management of patients with ulcerative colitis who have cancer or dysplasia, but the oncologic risk of stapled anastomosis vs mucosectomy with handsewn anastomosis is debated.
  • We compare the risk of new cancer or recurrence in the pouch or rectal cuff in patients with ulcerative colitis undergoing stapled anastomosis vs mucosectomy with handsewn anastomosis.
  • The patients with ulcerative colitis associated with colorectal dysplasia or cancer who underwent ileal pouch-anal anastomosis between 1981 and 2009 were evaluated.
  • The development of dysplasia or cancer at ileoanal anastomosis or in the pelvic pouch was assessed.
  • RESULTS: Eighty-one patients underwent stapled (n = 59) or handsewn (n = 22) ileal pouch-anal anastomosis; 52 had evidence of dysplasia and 29 had colorectal cancer (24 colon; 5 rectum) at the time of surgery.
  • Two of 10 (20%) patients with handsewn anastomosis and 0% patients with stapled anastomosis developed metastatic cancer.
  • One patient with a 33-year history of colitis, a previously resected right-sided colon cancer, and subsequent high-grade dysplasia in the rectum underwent a handsewn pelvic pouch and developed an unresectable adenocarcinoma at the cuff 4 years later.
  • Of those patients, both colorectal cancer-related deaths were in patients with handsewn anastomoses.
  • CONCLUSIONS: Performing a stapled ileal pelvic anal anastomosis does not appear to be inferior to mucosectomy and handsewn anastomosis in oncologic outcome, and it seems appropriate in patients with ulcerative colitis associated with coexisting dysplasia or cancer.


26. Tougeron D, Tougeron-Brousseau B, Nasser Z, Benzerroug M, Lefebure B, Hamidou H, Michel P, Muraine M: Unusual iris metastasis from anal cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e1-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual iris metastasis from anal cancer: a case report.
  • We report a case of anal cancer with iris metastasis and summarize the iris metastasis literature.
  • A 69 years old woman with a history of anal cancer presented with a visual field loss.
  • Because of worse prognosis of metastatic cancer and any ocular complications, the patient was treated by radiotherapy which allowed a clinical improvement.
  • Anal carcinoma can metastasize to the iris.
  • [MeSH-major] Anus Neoplasms / pathology. Iris Neoplasms / secondary

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294934.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Hirche C, Dresel S, Krempien R, Hünerbein M: Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience. Ann Surg Oncol; 2010 Sep;17(9):2357-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience.
  • BACKGROUND: There is some evidence that sentinel lymph node (SLN) biopsy guided by dye injection and/or radioisotopes can improve staging of inguinal lymph nodes (LNs) in anal cancer.
  • This study was performed to investigate the feasibility of fluorescence detection of SLN and lymphatic mapping in anal cancer.
  • METHODS: Twelve patients with anal cancer without evidence for inguinal LN involvement were included in the study.
  • Metastatic involvement of the SLN was found in 2 of 10 patients versus 2 of 9 patients.
  • Patients with metastatic involvement of the SLN received extended radiation field with inguinal boost.
  • CONCLUSIONS: ICG fluorescence imaging allows intraoperative lymphatic mapping and transcutaneous SLN detection for selective biopsy of inguinal SLN in anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Indocyanine Green. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Mar;18(3):901; author reply 902 [20717732.001]
  • (PMID = 20217256.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


29. Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD: Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis Colon Rectum; 2008 Jul;51(7):1061-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma: good results with aggressive therapy.
  • PURPOSE: To evaluate the clinical features, pathology, treatment, and outcome of patients with fistula-associated anal adenocarcinoma.
  • METHODS: We identified 14 patients with histologically proven fistula-associated anal adenocarcinoma.
  • Eleven patients had preexisting chronic anal fistulas.
  • The diagnosis of cancer was suspected during physical examination in 6 of the 14 patients (43 percent).
  • Four patients died with metastatic disease.
  • CONCLUSIONS: The diagnosis of fistula-associated anal adenocarcinoma is often unsuspected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418652.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • One patient had metastatic disease at diagnosis.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Zmora O, Spector D, Dotan I, Klausner JM, Rabau M, Tulchinsky H: Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer? Int J Colorectal Dis; 2009 Oct;24(10):1181-6
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer?
  • PURPOSE: The purpose of this study was to investigate the oncological and clinical outcome of ulcerative colitis (UC) patients with coexisting colorectal cancer/dysplasia following stapled ileal pouch-anal anastomosis (IPAA).
  • They were divided into three groups: colorectal cancer, dysplasia, and no cancer/dysplasia.
  • RESULTS: Sixteen patients had cancer and 14 had dysplasia.
  • Two of the three cancer patients who developed metastatic disease died.
  • One patient who had rectal cancer was found to have cancer cells in the rectal cuff 10 years after IPAA.
  • All other cancer/dysplasia patients were disease-free at 62 months (median).
  • The 5-year survival rate was 87.5% for the cancer group and 100% for the others (p < 0.0001).
  • Two rectal cancer patients who received radiotherapy did not maintain a functioning pouch.
  • Overall pouch failure rates were 19%, 7%, and 6% for cancer, dysplasia, and no-cancer/dysplasia patients, respectively (p = 0.13).
  • CONCLUSIONS: Stapled IPAA is a reasonable option for UC patients with cancer/dysplasia.
  • Close long-term follow-up for UC patients with cancer/dysplasia is recommended for early detection of possible recurrence.


32. Song JW, Cavnar SP, Walker AC, Luker KE, Gupta M, Tung YC, Luker GD, Takayama S: Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS One; 2009 Jun 01;4(6):e5756
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells.
  • BACKGROUND: The ability to properly model intravascular steps in metastasis is essential in identifying key physical, cellular, and molecular determinants that can be targeted therapeutically to prevent metastatic disease.
  • METHODOLOGY/PRINCIPAL FINDINGS: We present a microfluidic vasculature system to model interactions between circulating breast cancer cells with microvascular endothelium at potential sites of metastasis.
  • CONCLUSIONS/SIGNIFICANCE: When added from the basal side, CXCL12 acts through receptor CXCR4 on endothelium to promote adhesion of circulating breast cancer cells, independent of CXCL12 receptors CXCR4 or CXCR7 on tumor cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):401-20 [17717637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18886-91 [18006663.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Dec;293(6):C1824-33 [17913848.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] Annu Rev Physiol. 1995;57:827-72 [7778885.001]
  • [Cites] Diabetologia. 1995 Apr;38(4):474-80 [7796989.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] J Biol Chem. 1998 Feb 13;273(7):4282-7 [9461627.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):565-8 [9560152.001]
  • [Cites] Biophys J. 1998 Aug;75(2):721-33 [9675174.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:379-84 [15574376.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):465-72 [15695388.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):969-73 [15959517.001]
  • [Cites] Anal Chem. 2005 Jul 1;77(13):3993-9 [15987102.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):591-602 [16056258.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5453-9 [16131052.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):610-21 [16467548.001]
  • [Cites] Adv Drug Deliv Rev. 1998 Aug 3;33(1-2):141-64 [10837657.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):495-506 [10952719.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4478-85 [11296290.001]
  • [Cites] Nat Immunol. 2001 Jun;2(6):515-22 [11376338.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6540-7 [11522652.001]
  • [Cites] Physiol Genomics. 2001 Oct 10;7(1):55-63 [11595792.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):255-62 [12220670.001]
  • [Cites] Biorheology. 2003;40(1-3):41-5 [12454385.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7328-34 [12499276.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):257-62 [12414810.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2667-74 [12468429.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Nat Med. 2003 Jul;9(7):969-73 [12819780.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6751-7 [14583470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13081-6 [14569029.001]
  • [Cites] Trends Pharmacol Sci. 2003 Dec;24(12):640-7 [14654305.001]
  • [Cites] J Exp Med. 2004 Oct 4;200(7):935-9 [15466624.001]
  • [Cites] In Vitro. 1978 Nov;14(11):911-5 [730202.001]
  • [Cites] Endocr Rev. 1988 Feb;9(1):57-66 [3286235.001]
  • [Cites] Am J Physiol. 1990 Mar;258(3 Pt 2):H647-54 [2316679.001]
  • [Cites] Immunol Lett. 1990 Sep;25(4):331-40 [2249877.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2609-19 [7685772.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):30-41 [16046252.001]
  • [Cites] Nat Med. 2006 Aug;12(8):895-904 [16892035.001]
  • [Cites] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):573-87 [17165132.001]
  • [Cites] Anal Chem. 2007 Feb 1;79(3):1126-34 [17263345.001]
  • [Cites] Anal Chem. 2007 May 1;79(9):3504-8 [17388566.001]
  • [Cites] Virology. 2007 Jun 20;363(1):48-58 [17331554.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:121-67 [17373886.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):479-90 [18268039.001]
  • [Cites] Nat Immunol. 2008 Sep;9(9):949-52 [18711431.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1262-72 [18697212.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1331-9 [19141863.001]
  • (PMID = 19484126.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL084370-04; United States / NCI NIH HHS / CA / R01 CA136829; United States / NCI NIH HHS / CA / 1 R01 CA136829; United States / NHLBI NIH HHS / HL / HL084370; United States / NHLBI NIH HHS / HL / R01 HL084370-04; United States / NHLBI NIH HHS / HL / R01 HL084370; United States / NCI NIH HHS / CA / R01 CA136553; United States / NCI NIH HHS / CA / 1 R01 CA136553; United States / NCI NIH HHS / CA / P50 CA093990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / CXCR7 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR; 0 / Receptors, CXCR4; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2684591
  •  go-up   go-down


33. Homsi J, Garrett C: Melanoma of the anal canal: a case series. Dis Colon Rectum; 2007 Jul;50(7):1004-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anal canal: a case series.
  • PURPOSE: Anal melanoma is an uncommon and aggressive cancer.
  • METHODS: The medical records of patients with anal melanoma treated at the H.
  • Lee Moffitt Cancer and Research Institute between 1987 and 2004 were reviewed.
  • Published anal melanoma studies, including more than ten patients with outcome data, also were reviewed.
  • RESULTS: Twelve patients were identified (8 percent of all cancer of the anal canal).
  • Five of the 11 patients without metastatic disease relapsed or died within the first year of diagnosis (4 had local excision and 1 had abdominoperineal resection).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468984.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


34. Spugnini EP, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In Vivo; 2008 Jan-Feb;22(1):47-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog.
  • Canine anal sac gland carcinoma (ASGC) is a frequently described neoplasm that is highly aggressive and can frequently lead to metastatic spread.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Anal Sacs / drug effects. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396781.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Donigan M, Loh BD, Norcross LS, Li S, Williamson PR, DeJesus S, Ferrara A, Gallagher JT, Baker CH: A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc; 2010 Mar;24(3):642-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A metastatic colon cancer model using nonoperative transanal rectal injection.
  • BACKGROUND: This study aimed to develop a noninvasive orthotopic model for metastasis of colon and rectal cancer using a transanal approach.
  • Currently, the most accurate orthotopic representation of metastatic human colon cancer is via a cecal injection.
  • METHODS: For this study, 60 Balb/c mice were anesthetized and subjected to gentle anal dilation using blunt-tipped forceps at the anal opening.
  • Murine colon cancer parental CT26 or luciferase-labeled CT26 (CT26-luc) cells were injected submucosally into the distal posterior rectum (30 CT26 and 30 CT26 injections) at concentrations of 2.5 x 10(4), 1 x 10(5), and 1 x 10(6) in a volume of 50 microl.
  • Tumor growth and metastatic development was monitored at 5-day intervals for 50 days.
  • Two mice (3.3%) from the 2.5 x 10(4) CT26-luc group showed metastatic colonic adenocarcinoma to the liver on postinjection day 50.
  • CONCLUSION: Transanal rectal injection of colon cancer cells offers a nonoperative orthotopic murine model for colon cancer that may lead to the development of metastasis.
  • By using an orthotopic model, more aspects of metastatic colon cancer can be evaluated without the influence of a previous abdominal incision.
  • [MeSH-major] Colonic Neoplasms / secondary. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Line, Tumor. Disease Models, Animal. Injections / methods. Mice. Mice, Inbred BALB C

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688392.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Iagaru A, Kundu R, Jadvar H, Nagle D: Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med; 2009 Jan-Apr;12(1):26-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
  • Anal squamous cell carcinoma (ASCC) is a rare cancer of the gastrointestinal tract, representing less than 5% of the digestive malignancies.
  • Our results showed that PET demonstrated the primary lesion at initial evaluation in 7 of 8 anal cancers and showed FDG- avid lymph nodes in 4 patients.
  • Metastatic nodal involvement was confirmed by pathology in 2 patients; in the other 2 patients pathology showed reactive follicular hyperplasia.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330178.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Meyer A, Bruns F, Richter K, Grünwald V, Karstens JH: Small cell cancer of the anal canal--case report of a rare tumor. Anticancer Res; 2007 Mar-Apr;27(2):1047-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell cancer of the anal canal--case report of a rare tumor.
  • BACKGROUND: We report on a rare case of small cell cancer located at the anal canal.
  • CASE REPORT: A 41-year old woman presented with locally advanced small cell anal cancer and simultaneous hepatic and pulmonal deposits.
  • Due to metastatic disease, chemotherapy with etoposide and cisplatin was performed with mixed response after four cycles of chemotherapy.
  • CONCLUSION: In patients with metastatic small cell anal cancer chemotherapy remains the mainstay of therapy.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465242.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


38. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z: A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis; 2009 Jun;24(6):677-85
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
  • PURPOSE: Bevacizumab has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients when combined with chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184059.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


39. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • The patient was administered chemotherapy with 5-fluorouracil and cisplatin (5-FU/CDDP) to the metastatic lymph node.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


40. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The combination of the EGFR antagonist cetuximab with cisplatin has shown modest success in other metastatic SCCs.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


41. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R: Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology; 2010;220(1):77-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
  • Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.
  • We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996579.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


42. Sharma N, Saifo M, Tamaskar IR, Bhuvaneswari R, Mashtare T, Fakih M: KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. J Gastrointest Oncol; 2010 Dec;1(2):90-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.
  • BACKGROUND: Two previous first-line studies showed an improved trend in response rate (RR) and progression free survival (PFS) in metastatic colorectal cancer (CRC) patients with KRAS mutation.
  • Others have reported a worsened outlook for metastatic CRC patients with KRAS mutation and a higher likelihood of metastatic disease to the lungs.
  • In this study, we aimed to address the impact of KRAS on the pattern of metastatic disease at presentation and on RR and PFS with first-line 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy.
  • METHODS: Patients with CRC who underwent KRAS testing using DxS assay at Roswell Park Cancer Institute (RPCI) were identified.
  • Patients with metastatic CRC treated with first-line FOLFOX +/- bevacizumab were assessed for response and survival using RECIST 1.1 guidelines.
  • RESULTS: 181 patients with metastatic CRC and KRAS testing were identified.
  • CONCLUSION: In this single institute study, our findings do not support any predictive role for KRAS-MT in terms of response to FOLFOX first-line chemotherapy, or in terms of sites of metastatic disease at mCRC presentation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1992 Mar 20;68(6):1041-50 [1312393.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1221-6 [1847659.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1133-8 [7557947.001]
  • [Cites] J Clin Lab Anal. 1995;9(5):297-301 [8531010.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1375-81 [10334521.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):981-9 [15998951.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):663-71 [19114683.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] PLoS One. 2009;4(12):e8199 [20020061.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):747-51 [7989112.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):57-64 [8419262.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Chem Biol Interact. 2004 Dec 30;151(1):33-42 [15607760.001]
  • [Cites] J Biochem Mol Toxicol. 2005;19(6):359-67 [16421893.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] N Engl J Med. 2009 Feb 5;360(6):563-72 [19196673.001]
  • [Cites] EMBO J. 1992 Feb;11(2):569-74 [1371463.001]
  • (PMID = 22811812.001).
  • [ISSN] 2219-679X
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3397582
  • [Keywords] NOTNLM ; FOLFOX / KRAS / cetuximab / metastatic colorectal cancer
  •  go-up   go-down


43. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL: Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest; 2007 May;117(5):1305-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
  • Using the MMTV/PyVmT transgenic model of metastatic breast cancer, we show that administration of ionizing radiation or doxorubicin caused increased circulating levels of TGF-beta1 as well as increased circulating tumor cells and lung metastases.
  • Radiation failed to enhance lung metastases in mice bearing tumors that lack the type II TGF-beta receptor, suggesting that the increase in metastases was due, at least in part, to a direct effect of TGF-beta on the cancer cells.
  • These data implicate TGF-beta induced by anticancer therapy as a pro-metastatic signal in tumor cells and provide a rationale for the simultaneous use of these therapies in combination with TGF-beta inhibitors.

  • Genetic Alliance. consumer health - Radiation induced cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):506-20 [16794634.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1551-9 [12070302.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):487-94 [12105419.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e245-60 [12456378.001]
  • [Cites] Invest New Drugs. 2003 Feb;21(1):21-32 [12795527.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):531-6 [12842082.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5 [12808151.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):237-45 [14568692.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8691-703 [14612410.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):807-21 [14557817.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4523-30 [15231662.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):269-78 [15260977.001]
  • [Cites] J Immunol. 1990 Sep 1;145(5):1415-22 [2384664.001]
  • [Cites] Cell Growth Differ. 1993 Mar;4(3):193-201 [8466857.001]
  • [Cites] N Engl J Med. 1993 Jun 3;328(22):1592-8 [8487801.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):599-610 [10675495.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2504-11 [10811132.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18234-42 [10748131.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):58-65 [10862196.001]
  • [Cites] Semin Radiat Oncol. 2000 Oct;10(4):296-307 [11040330.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1258-62 [11350892.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2856-64 [11387358.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3328-39 [11694570.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):2985-92 [11753975.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2569-76 [7504687.001]
  • [Cites] J Clin Invest. 1994 Feb;93(2):892-9 [8113421.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] Cancer Lett. 1995 Feb 10;89(1):45-8 [7882301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1115-23 [9169821.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):453-61 [9509295.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):463-72 [9509296.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):554-61 [10091729.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):231-43 [10336800.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9002-11 [15604265.001]
  • [Cites] Oral Oncol. 2005 Feb;41(2):208-13 [15695123.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10870-6 [15657037.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2296-302 [15781643.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4703-15 [15899872.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):516-25 [15965493.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):30-7 [16377175.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):876-81 [16751069.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3408-23 [16186809.001]
  • [Cites] Genesis. 2002 Feb;32(2):73-5 [11857781.001]
  • (PMID = 17415413.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA062212; United States / NCI NIH HHS / CA / R01 CA 62212; United States / NCI NIH HHS / CA / R01 CA 102162; United States / NCI NIH HHS / CA / P50 CA098131; United States / NCI NIH HHS / CA / R01 CA102162; United States / NCI NIH HHS / CA / P30 CA 68485; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / R01 CA 38079; United States / NCI NIH HHS / CA / P50 CA 98131; United States / NCI NIH HHS / CA / R01 CA 85492; United States / NCI NIH HHS / CA / R01 CA038079; United States / NCI NIH HHS / CA / R01 CA085492
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Antigens, Polyomavirus Transforming; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC1838926
  •  go-up   go-down


44. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol; 2009 Dec;65(1):197-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?
  • PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours.
  • The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated.
  • This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease.
  • [MeSH-major] Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727729.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


45. Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J, Sweeney CJ, Novotny MV: Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res; 2007 May;6(5):1822-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in the serum glycome due to metastatic prostate cancer.
  • Glycomic profiles derived from human blood sera of 10 healthy males were compared to those from 24 prostate cancer patients.
  • The first principal component distinguished the 24 prostate cancer patients from the healthy individuals.
  • It was determined that fucosylation of glycan structures is generally higher in cancer samples (ANOVA test p-value of 0.0006).
  • Ten of these structures had significantly higher relative intensities in the case of the cancer samples, while the other two were less abundant in the cancer samples.
  • Accordingly, these structures can be considered as cancer-specific glycans and potential prostate cancer biomarkers.
  • Therefore, serum glycomic profiling appears worthy of further investigation to define its role in cancer early detection and prognostication.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1410-6 [10728707.001]
  • [Cites] Biomarkers. 2006 Sep-Oct;11(5):406-16 [16966158.001]
  • [Cites] Proteomics. 2001 Feb;1(2):311-28 [11680878.001]
  • [Cites] Proteomics. 2001 Oct;1(10):1264-70 [11721637.001]
  • [Cites] Glycobiology. 2002 Jan;12(1):47-63 [11825886.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Apr;128(4):189-96 [11935309.001]
  • [Cites] Glycobiology. 2002 Mar;12(3):153-62 [11971859.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1251-5 [12375029.001]
  • [Cites] Anal Sci. 2003 Jan;19(1):85-92 [12558029.001]
  • [Cites] Biol Chem. 2003 Feb;384(2):321-7 [12675527.001]
  • [Cites] Glycobiology. 2003 Jun;13(6):457-70 [12626390.001]
  • [Cites] Biochimie. 2003 Jan-Feb;85(1-2):207-18 [12765790.001]
  • [Cites] Science. 2003 Jul 11;301(5630):159-60 [12855785.001]
  • [Cites] Korean J Radiol. 2004 Jan-Mar;5(1):11-8 [15064554.001]
  • [Cites] Clin Chem. 2004 Jun;50(6):1017-25 [15054080.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Science. 1988 Jun 3;240(4857):1285-93 [3287615.001]
  • [Cites] Neoplasma. 1988;35(6):691-705 [3265486.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Jan;25(1):65-72 [2920769.001]
  • [Cites] J Urol. 1994 Jun;151(6):1571-4 [7514690.001]
  • [Cites] J Chromatogr A. 1996 Jan 12;720(1-2):429-46 [8601205.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Anal Chem. 1998 Feb 1;70(3):455-63 [9470483.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Glycobiology. 2007 Apr;17(4):411-22 [17223647.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Glycoconj J. 2009 Feb;26(2):117-31 [18752066.001]
  • [Cites] J Clin Lab Anal. 1998;12(1):6-13 [9484663.001]
  • [Cites] Clin Chim Acta. 1998 Mar 23;271(2):191-202 [9565334.001]
  • [Cites] Glycobiology. 1998 Jun;8(6):605-13 [9592127.001]
  • [Cites] Glycoconj J. 1998 Apr;15(4):323-31 [9613818.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1597-602 [9990070.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Feb;32(2):275-80 [15751649.001]
  • [Cites] Curr Opin Urol. 2005 May;15(3):151-6 [15815190.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2969-73 [15837749.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1289-97 [16211224.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(23):3421-8 [16252310.001]
  • [Cites] Biochemistry. 2005 Nov 29;44(47):15619-35 [16300412.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):1977-89 [16170054.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] Biometrics. 2006 Mar;62(1):221-9 [16542249.001]
  • [Cites] Electrophoresis. 2006 Apr;27(8):1609-16 [16550497.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):231-6 [16678055.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] CA Cancer J Clin. 1999 Sep-Oct;49(5):264-81 [11198954.001]
  • (PMID = 17432893.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR018942; United States / NIGMS NIH HHS / GM / R01 GM024349; United States / NIGMS NIH HHS / GM / GM24349; United States / NCRR NIH HHS / RR / RR018942
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Glycoproteins; 0 / Polysaccharides
  • [Other-IDs] NLM/ NIHMS62933; NLM/ PMC3685170
  •  go-up   go-down


46. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer; 2007 Jul 15;121(2):257-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
  • More recently, activating KIT mutations have been described in rare cases of metastatic melanoma, without further reference to their clinical phenotypes.
  • In this study, we investigated a group of anal melanomas for the presence of BRAF, NRAS, KIT and PDGFRA mutations.
  • No BRAF or PDGFRA mutations were identified in either KIT positive or negative anal melanomas.
  • These results suggest that a subset of anal melanomas show activating KIT mutations, which are susceptible for therapy with specific kinase inhibitors.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17372901.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / P30 CA008748; United States / NIDDK NIH HHS / DK / HL/DK55748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; RBZ1571X5H / Dasatinib
  •  go-up   go-down


47. Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, Asensio G, Jordá L, Estrela JM: Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia; 2005 Jan;7(1):37-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma.
  • Inhibition of cancer growth by resveratrol (trans-3,5,4'-trihydroxystilbene; RESV), a phytoalexin present in many plant species, is limited by its low bioavailability.
  • Intravenous administration of PTER and QUER (20 mg/kg per day) to mice inhibits (73%) metastatic growth of B16M-F10 cell in the liver, a common site for metastasis development.
  • The anti-metastatic mechanism involves:.
  • 1) a PTER-induced inhibition of vascular adhesion molecule 1 expression in the hepatic sinusoidal endothelium, which consequently decreases B16M-F10 cell adhesion to the endothelium through very late activation antigen 4; and 2) a QUER- and PTER-induced inhibition of Bcl-2 expression in metastatic cells, which sensitizes them to vascular endothelium-induced cytotoxicity.
  • Our findings demonstrate that the association of PTER and QUER inhibits metastatic melanoma growth and extends host survival.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Free Radic Biol Med. 1997;22(7):1203-9 [9098094.001]
  • [Cites] J Cell Physiol. 1998 Mar;174(3):322-30 [9462694.001]
  • [Cites] FEBS Lett. 1998 Jan 16;421(3):277-9 [9468322.001]
  • [Cites] J Nat Prod. 1998 Mar;61(3):362-6 [9544566.001]
  • [Cites] Hepatology. 1998 May;27(5):1249-56 [9581678.001]
  • [Cites] Clin Chem. 1998 Jul;44(7):1423-9 [9665419.001]
  • [Cites] Blood. 1998 Aug 1;92(3):996-1002 [9680369.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21875-82 [9705326.001]
  • [Cites] Nutr Rev. 1998 Nov;56(11):317-33 [9838798.001]
  • [Cites] Life Sci. 1999;64(21):1869-76 [10353585.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2596-601 [10363980.001]
  • [Cites] Biochemistry. 1999 Oct 5;38(40):13244-51 [10529197.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]
  • [Cites] J Pathol. 2000 Feb;190(3):310-29 [10685065.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):567-74 [10845555.001]
  • [Cites] Altern Med Rev. 2000 Jun;5(3):196-208 [10869101.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1619-22 [10910967.001]
  • [Cites] Free Radic Biol Med. 2000 Dec 15;29(12):1234-43 [11118813.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1604-10 [11245472.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1205-15 [11322924.001]
  • [Cites] Annu Rev Nutr. 2001;21:381-406 [11375442.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22586-94 [11316812.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1613-5 [11427503.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25775-82 [11313348.001]
  • [Cites] Clin Exp Metastasis. 2000;18(5):415-21 [11467774.001]
  • [Cites] Adv Exp Med Biol. 2001;492:159-82 [11480664.001]
  • [Cites] Cancer Lett. 2001 Sep 28;171(1):11-6 [11485823.001]
  • [Cites] Cell Physiol Biochem. 2001;11(4):173-86 [11509825.001]
  • [Cites] Free Radic Biol Med. 2001 Sep 1;31(5):642-50 [11522449.001]
  • [Cites] J Agric Food Chem. 2002 Jun 5;50(12):3453-7 [12033810.001]
  • [Cites] Annu Rev Nutr. 2002;22:19-34 [12055336.001]
  • [Cites] Free Radic Biol Med. 2002 Aug 1;33(3):387-98 [12126761.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):79-87 [12554065.001]
  • [Cites] BMC Cancer. 2002 Oct 17;2:27 [12383351.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13888-97 [12578841.001]
  • [Cites] J Cell Biochem. 2003 Aug 1;89(5):1044-55 [12874837.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39591-9 [12881529.001]
  • [Cites] FASEB J. 2003 Nov;17(14):1975-85 [14597667.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2339-41 [14563682.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):829-37 [15019968.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):838-49 [15019969.001]
  • [Cites] J Theor Biol. 1985 Jun 7;114(3):413-31 [4021503.001]
  • [Cites] J Natl Cancer Inst. 1986 Jun;76(6):1247-54 [3486997.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Jpn J Cancer Res. 1989 Sep;80(9):818-21 [2513297.001]
  • [Cites] Anal Chem. 1989 Dec 15;61(24):2715-8 [2619057.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6676-81 [1423313.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3233-6 [7515767.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):414-9 [7529137.001]
  • [Cites] Biochem Soc Symp. 1995;61:1-31 [8660387.001]
  • [Cites] Ann Intern Med. 1996 Sep 1;125(5):384-9 [8702089.001]
  • (PMID = 15736313.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alpha4beta1; 0 / Nitrates; 0 / Nitrites; 0 / Phenols; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Stilbenes; 0 / Vascular Cell Adhesion Molecule-1; 537-42-8 / pterostilbene; 9IKM0I5T1E / Quercetin; BBX060AN9V / Hydrogen Peroxide
  • [Other-IDs] NLM/ PMC1490314
  •  go-up   go-down


48. Gujral DM, Bhattacharyya S, Hargreaves P, Middleton GW: Metastatic rectal adenocarcinoma within haemorrhoids: a case report. J Med Case Rep; 2008;2:128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic rectal adenocarcinoma within haemorrhoids: a case report.
  • INTRODUCTION: Metastatic tumour involvement of the anal canal is rare.
  • CASE PRESENTATION: We report the case of a 69-year-old woman with metastatic colorectal carcinoma who presented with metastatic carcinoma within thrombosed haemorrhoids.
  • CONCLUSION: We suggest that in patients with colorectal cancer, careful examination of haemorrhoids on colonoscopy as well as histological examination of suspected haemorrhoidal tissue after surgical resection be performed to evaluate for metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 1985 Dec;61(722):1081 [4095054.001]
  • [Cites] Dis Colon Rectum. 1968 May-Jun;11(3):213-9 [5666898.001]
  • [Cites] Am Surg. 2000 Aug;66(8):789-92 [10966042.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Feb;29(2):213-4; author reply 214-5 [15795679.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):856-8 [12088459.001]
  • [Cites] Surg Gynecol Obstet. 1992 Apr;174(4):302-4 [1553609.001]
  • [Cites] Dis Colon Rectum. 1975 Jan-Feb;18(1):42-8 [1126255.001]
  • (PMID = 18442399.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2386132
  •  go-up   go-down


49. Cunha IW, Carvalho KC, Martins WK, Marques SM, Muto NH, Falzoni R, Rocha RM, Aguiar S, Simoes AC, Fahham L, Neves EJ, Soares FA, Reis LF: Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol; 2010 Feb;3(1):23-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors.
  • Soft tissue tumors represent a group of neoplasia with different histologic and biological presentations varying from benign, locally confined to very aggressive and metastatic tumors.
  • Using 102 tumor samples representing a large spectrum of these tumors, we performed expression profiling and defined differentially expression genes that are likely to be involved in tumors that are locally aggressive and in tumors with metastatic potential.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1063-9 [15252314.001]
  • [Cites] Cell Prolif. 2004 Apr;37(2):161-75 [15030550.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7201-4 [15492233.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):611-22 [15548371.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2192-201 [15914641.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):4049-57 [16129888.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):487-98 [16428491.001]
  • [Cites] Liver Int. 2006 May;26(4):424-32 [16629645.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 1;168(1):30-5 [16772118.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):5-24 [16773180.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):447-57 [16981854.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):404-10 [17122636.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Cell Signal. 2007 Jun;19(6):1315-27 [17336041.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13759-68 [17337440.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16401-12 [17412687.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):955-65 [17450526.001]
  • [Cites] Free Radic Biol Med. 2007 Jun 1;42(11):1704-14 [17462538.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):876-84 [17479401.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):885-94 [17479402.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):895-900 [17479403.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3121-32 [17717065.001]
  • [Cites] Semin Thromb Hemost. 2007 Oct;33(7):667-72 [18000793.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1734-43 [18347174.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2814-23 [19109576.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Cytotechnology. 1996;19(3):253-6 [8862015.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1956-66 [9528767.001]
  • [Cites] Oncogene. 1998 Oct 22;17(16):2039-45 [9798675.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):484-5 [11831227.001]
  • [Cites] Circ Res. 2002 Mar 22;90(5):506-8 [11909813.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5859-66 [12384549.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):549-58 [12827608.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):244-51 [14511690.001]
  • [Cites] Clin Exp Metastasis. 2003;20(7):665-74 [14669798.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):235-40 [14685255.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):516-23 [14696115.001]
  • [Cites] Ai Zheng. 2004 Mar;23(3):264-8 [15025954.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8997-9006 [15467746.001]
  • (PMID = 20165692.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2822450
  •  go-up   go-down


50. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic potential of an aneurysmal bone cyst.
  • We herewith document a case of a pelvic ABC metastatic to the lung, liver, and kidneys.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


51. Bullitt E, Lin NU, Ewend MG, Zeng D, Winer EP, Carey LA, Smith JK: Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Med Image Comput Comput Assist Interv; 2006;9(Pt 2):561-8
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer.
  • This report is the first to describe the changes in vessel shape that occur during treatment of metastatic brain tumors as assessed by sequential MRA.
  • In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer we conclude that vessel shape may predict tumor response several months in advance of traditional methods.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):612-9 [16552004.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] Med Image Anal. 2001 Jun;5(2):157-69 [11516709.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):38-46 [16443946.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):770-6 [15814919.001]
  • [Cites] Acad Radiol. 2005 Oct;12(10):1232-40 [16179200.001]
  • (PMID = 17354817.001).
  • [Journal-full-title] Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention
  • [ISO-abbreviation] Med Image Comput Comput Assist Interv
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000046; United States / NCI NIH HHS / CA / P50 CA058185; United States / NIBIB NIH HHS / EB / R01EB000219; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / P30CA16086-29S1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NCI NIH HHS / CA / T32 CA009172; United States / NCRR NIH HHS / RR / M01RR00046; United States / NIBIB NIH HHS / EB / R01 EB000219-09; None / None / / R01 EB000219-09; United States / NCI NIH HHS / CA / P30CA58223; United States / NCI NIH HHS / CA / P50CA58186-AV-55P2
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  • [Other-IDs] NLM/ NIHMS53779; NLM/ PMC2504703
  •  go-up   go-down


52. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer; 2007 Jan 03;7:2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.
  • BACKGROUND: Many breast, pancreatic, colonic and non-small-cell lung carcinoma lines express CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen, CEA), and antibodies to both can affect tumor cell growth in vitro and in vivo.
  • Here, we compare both antigens as a function of histological phenotype in breast, pancreatic, lung, ovarian, and prostatic cancers, including patient-matched normal, primary tumor, and metastatic breast and colonic cancer specimens.
  • In breast tumors, CEACAM6 was highest in papillary > infiltrating ductal > lobular > phyllodes; in pancreatic tumors, moderately-differentiated > well-differentiated > poorly-differentiated tumors; mucinous ovarian adenocarcinomas had almost 3-fold more CEACAM6 than serous ovarian adenocarcinomas; lung adenocarcinomas > squamous tumors; and liver metastases of colonic carcinoma > primary tumors = lymph nodes metastases > normal intestine.
  • However, CEACAM6 expression was similar in prostate cancer and normal tissues.
  • The amount of CEACAM6 in metastatic colon tumors found in liver was higher than in many primary colon tumors.
  • Based on previous work demonstrating a role for CEACAM6 in tumor cell migration, invasion and adhesion, and formation of distant metastases (Blumenthal et al., Cancer Res 65: 8809-8817, 2005), it may be a promising target for antibody-based therapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] Cancer Metastasis Rev. 1998 Jun;17(2):177-85 [9770114.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):315-27 [15592930.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):491-6 [15729073.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5084-9 [16033821.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8809-17 [16204051.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6C):5599-606 [10697625.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3419-24 [10910050.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2022-30 [11448920.001]
  • [Cites] Exp Cell Res. 1999 Nov 1;252(2):243-9 [11501563.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):433-5 [11874075.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):713-8 [12235205.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8683-95 [12483521.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):413-23 [12872364.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]
  • [Cites] Pathol Res Pract. 2003;199(11):705-12 [14708636.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):465-73 [14724575.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):133-41 [15047158.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):837-43 [15081416.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23176-82 [15047698.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3987-93 [15173012.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5834-42 [15208677.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1384-90 [15316565.001]
  • [Cites] J Exp Med. 1965 Sep 1;122(3):467-81 [4953873.001]
  • [Cites] J Natl Cancer Inst. 1976 Jul;57(1):11-22 [794493.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):686-92 [6184152.001]
  • [Cites] Crit Rev Oncol Hematol. 1985;2(4):355-99 [3886178.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Oct 16;164(1):39-45 [2803308.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6987-94 [1698547.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jan 31;182(2):501-6 [1370882.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3478-85 [7683969.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):130-6 [8318403.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3817-22 [7687926.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):262-8 [7690347.001]
  • [Cites] Cancer Lett. 1995 May 25;92(1):59-66 [7757961.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5935s-5945s [7493374.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 27;219(3):842-7 [8645267.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):200-5 [9085168.001]
  • [Cites] Jpn J Cancer Res. 1998 Feb;89(2):177-85 [9548445.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1559-64 [15634649.001]
  • (PMID = 17201906.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099529; United States / NCI NIH HHS / CA / R01 CA99529
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins
  • [Other-IDs] NLM/ PMC1769503
  •  go-up   go-down


53. Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM: Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A; 2007 Jun 12;104(24):10170-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.
  • Recently, there have been attempts to develop cancer treatment by using tumor-targeting bacteria.
  • We have developed a far more effective bacterial cancer therapy by targeting viable tumor tissue by using Salmonella typhimurium leu-arg auxotrophs.
  • A1-R was used to treat metastatic PC-3 human prostate tumors that had been orthotopically implanted in nude mice.
  • GFP was used to image tumor and metastatic growth.
  • The approach described here, where bacterial monotherapy effectively treats metastatic prostate tumors, is a significant improvement over previous bacterial tumor-therapy strategies that require combination with toxic chemotherapy.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60 [11724950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9814-8 [11481427.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):87-98 [12832111.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):548-56 [12965276.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):964-72 [12879198.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15083-8 [14657371.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4251-6 [15205338.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15172-7 [15471990.001]
  • [Cites] Gan. 1978 Oct;69(5):613-8 [729960.001]
  • [Cites] Cancer Res. 1980 Jun;40(6):2061-8 [6989495.001]
  • [Cites] Nature. 1981 May 21;291(5812):238-9 [7015147.001]
  • [Cites] Gene Ther. 1996 Feb;3(2):173-8 [8867865.001]
  • [Cites] Gene Ther. 1997 Aug;4(8):791-6 [9338007.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4537-44 [9377566.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):37-41 [9920266.001]
  • [Cites] Cancer Res. 1955 Aug;15(7):473-8 [13240693.001]
  • [Cites] Cancer Res. 1964 Feb;24:212-6 [14115686.001]
  • [Cites] Cancer Res. 1964 Feb;24:217-21 [14115687.001]
  • [Cites] Cancer Res. 1964 Feb;24:222-33 [14115688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60 [15644448.001]
  • [Cites] Prostate. 2005 Mar 1;62(4):374-9 [15389802.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7647-52 [16885365.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1120-8 [16855381.001]
  • [Cites] Science. 2006 Nov 24;314(5803):1308-11 [17124324.001]
  • [Cites] Cancer Gene Ther. 2000 Feb;7(2):269-74 [10770636.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1027-30 [10772643.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1996-2002 [10837181.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):165-70 [11437103.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):142-52 [11773163.001]
  • (PMID = 17548809.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 119841; United States / NCI NIH HHS / CA / R43 CA103563; United States / NCI NIH HHS / CA / R43 CA119841; United States / NCI NIH HHS / CA / CA 103563; United States / NCI NIH HHS / CA / R44 CA103563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC1891231
  •  go-up   go-down


54. Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ: Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology; 2008 Oct;18(10):806-17
GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.
  • Prostate cancer (PCa) cell tethering and rolling on microvascular endothelium has been proposed to promote the extravasation of PCa cells.
  • Prior data indicate that E-selectin-mediated rolling of bone-metastatic PCa MDA PCa 2b (MDA) cells is dependent on sialyl Lewis X (sLe(X))-bearing glycoproteins.
  • To explore the molecular basis of sLe(X) synthesis and E-selectin ligand (ESL) activity on PCa cells, we compared and contrasted the expression level of glycosyltransferases, characteristically involved in sLe(X) and ESL synthesis, in ESL(+) MDA cells among other ESL(-) metastatic PCa cell lines.
  • We found that normal prostate tissue and all metastatic PCa cell lines expressed glycosyltransferases required for sialo-lactosamine synthesis, including N-acetylglucosaminyl-, galactosyl-, and sialyltransferases.
  • These results implicate the importance of alpha1,3 FT3, FT6, and/or FT7 in sLe(X) and ESL synthesis on metastatic PCa cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500 [9815652.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2127-35 [10232599.001]
  • [Cites] Glycoconj J. 1998 Dec;15(12):1155-63 [10372971.001]
  • [Cites] Br J Cancer. 1999 Jun;80(8):1169-74 [10376968.001]
  • [Cites] Biochim Biophys Acta. 1999 Aug 5;1428(2-3):209-18 [10434038.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):70-9 [10449611.001]
  • [Cites] Clin Exp Immunol. 1999 Sep;117(3):430-4 [10469043.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1666-76 [15467730.001]
  • [Cites] Glycobiology. 2005 Mar;15(3):271-80 [15483269.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):875-9 [15868922.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):131-7 [15939404.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5750-60 [15994950.001]
  • [Cites] Biochim Biophys Acta. 2005 Oct 15;1731(1):66-73 [16199102.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):290-301 [16756721.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4742-8 [16982914.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31353-60 [10882744.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):558-65 [11058871.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4839-47 [11156243.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1130-2 [1701274.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):424-30 [1732113.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):972-7 [7687590.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1817-9 [7728744.001]
  • [Cites] Genomics. 1995 Mar 1;26(1):142-6 [7782074.001]
  • [Cites] Hum Pathol. 1995 Jul;26(7):735-9 [7628844.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):20112-22 [7650030.001]
  • [Cites] J Cell Biochem. 1995 Jul;58(3):292-304 [7593252.001]
  • [Cites] Int J Cancer. 1995 Nov 15;63(4):551-9 [7591266.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):219-28 [8548870.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):325-9 [8542587.001]
  • [Cites] J Biol Chem. 1996 Apr 26;271(17):10317-28 [8626601.001]
  • [Cites] J Cell Biol. 1996 May;133(4):911-20 [8666674.001]
  • [Cites] Anal Biochem. 1996 Jul 1;238(2):184-90 [8660609.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2125-32 [8822932.001]
  • [Cites] Glycoconj J. 1997 Jan;14(1):147-53 [9076523.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16100-6 [11278338.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1417-23 [11355957.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):17949-57 [11278609.001]
  • [Cites] J Cell Biol. 2001 Jun 11;153(6):1277-86 [11402070.001]
  • [Cites] Immunity. 2001 Jul;15(1):115-26 [11485743.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):601-14 [11535629.001]
  • [Cites] Glycobiology. 2001 Oct;11(10):119R-128R [11588153.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):25-33 [11918080.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4063-9 [12010808.001]
  • [Cites] Am Fam Physician. 2002 May 1;65(9):1834-40 [12018806.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):321-31 [12085969.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):559-69 [12189250.001]
  • [Cites] Immunol Rev. 2002 Aug;186:19-36 [12234359.001]
  • [Cites] Trends Immunol. 2003 Mar;24(3):101-4 [12615200.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Mar;84(4):411-22 [12732286.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):462-73 [12761880.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3805-11 [12839977.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2060-7 [12763924.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):531-8 [14519387.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):413-20 [14524530.001]
  • [Cites] Annu Rev Biochem. 2003;72:643-91 [12676797.001]
  • [Cites] Adv Exp Med Biol. 2001;491:267-78 [14533803.001]
  • [Cites] Adv Exp Med Biol. 2001;491:587-630 [14533823.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Sep;22(3):431-40 [14582703.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):949-57 [14601054.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2004 May 7;42(9):546-50 [15196369.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5261-9 [15289332.001]
  • [Cites] Cancer Lett. 2006 Oct 28;242(2):191-7 [16427187.001]
  • [Cites] Biol Pharm Bull. 2006 Dec;29(12):2372-7 [17142966.001]
  • [Cites] Expert Opin Ther Targets. 2007 Nov;11(11):1473-91 [18028011.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jan;121(1):148-157.e3 [17910894.001]
  • [Cites] J Biochem. 2008 Jun;143(6):725-9 [18218651.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1092-9 [18281484.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4011-9 [10590044.001]
  • [Cites] Mol Carcinog. 2000 Apr;27(4):280-8 [10747292.001]
  • [Cites] Immunity. 2000 Jun;12(6):665-76 [10894166.001]
  • [Cites] Leuk Lymphoma. 2000 Sep;39(1-2):185-94 [10975398.001]
  • [Cites] Glycobiology. 1997 Apr;7(3):357-65 [9147044.001]
  • [Cites] Glycobiology. 1997 Sep;7(6):835-46 [9376686.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29721-8 [9368041.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):118-23 [9450571.001]
  • [Cites] Glycoconj J. 1997 Nov;14(7):875-7 [9511995.001]
  • [Cites] Int J Oncol. 1998 May;12(5):1157-64 [9538143.001]
  • [Cites] Glycobiology. 1998 Jun;8(6):605-13 [9592127.001]
  • [Cites] J Immunol. 1998 Dec 1;161(11):6305-15 [9834120.001]
  • (PMID = 18647941.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118124; United States / NIAMS NIH HHS / AR / P30 AR042689; United States / NCI NIH HHS / CA / R01CA118124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / E-Selectin; 0 / Ligands; 0 / Oligosaccharides; EC 2.4.- / Glycosyltransferases
  • [Other-IDs] NLM/ NIHMS62214; NLM/ PMC2574550
  •  go-up   go-down


55. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum; 2007 Mar;50(3):395-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
  • Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease.
  • We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252287.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


56. Gazi E, Dwyer J, Lockyer NP, Gardner P, Shanks JH, Roulson J, Hart CA, Clarke NW, Brown MD: Biomolecular profiling of metastatic prostate cancer cells in bone marrow tissue using FTIR microspectroscopy: a pilot study. Anal Bioanal Chem; 2007 Mar;387(5):1621-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomolecular profiling of metastatic prostate cancer cells in bone marrow tissue using FTIR microspectroscopy: a pilot study.
  • Prostate cancer (CaP) cells preferentially metastasise to the bone marrow, a microenvironment that plays a substantial role in the sustenance and progression of the CaP tumour.
  • Here we use a combination of FTIR microspectroscopy and histological stains to increase molecular specificity and probe the biochemistry of metastatic CaP cells in bone marrow tissue derived from a limited source of paraffin-embedded biopsies of different patients.
  • This provides distinction between the following dominant metabolic processes driving the proliferation of the metastatic cells in each of these biopsies: glycerophospholipid synthesis from triacylglyceride, available from surrounding adipocytes, in specimen 1, through significantly high (p < or = 0.05) carbohydrate (8.23 +/- 1.44 cm(-1)), phosphate (6.13 +/- 1.5 cm(-1)) and lipid hydrocarbon (24.14 +/- 5.9 cm(-1)) signals compared with the organ-confined CaP control (OC CaP), together with vacuolation of cell cytoplasm; glycolipid synthesis in specimen 2, through significantly high (p < or = 0.05) carbohydrate (5.51 +/- 0.04 cm(-1)) and high lipid hydrocarbon (17.91 +/- 2.3 cm(-1)) compared with OC CaP, together with positive diastase-digested periodic acid Schiff staining in the majority of metastatic CaP cells; glycolysis in specimen 3, though significantly high (p < or = 0.05) carbohydrate (8.86 +/- 1.78 cm(-1)) and significantly lower (p < or = 0.05) lipid hydrocarbon (11.67 +/- 0.4 cm(-1)) than OC CaP, together with negative diastase-digested periodic acid Schiff staining in the majority of metastatic CaP cells.
  • Detailed understanding of the biochemistry underpinning the proliferation of tumour cells at metastatic sites may help towards refining chemotherapeutic treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow Neoplasms / metabolism. Bone Marrow Neoplasms / secondary. Lipids / chemistry. Prostatic Neoplasms / metabolism. Spectroscopy, Fourier Transform Infrared / methods

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268776.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Biopolymers; 0 / Lipids
  •  go-up   go-down


57. Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, Zhau HE, Marshall FF, Chung LW: Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol; 2010 Jul;58(1):162-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.
  • BACKGROUND: The tumor microenvironment is important for progressive and metastatic disease.
  • OBJECTIVE: To study the hypothesis that prostate fibroblasts have differential ability to induce castration-resistant prostate cancer (PCa) and metastatic progression and whether this effect might vary depending on the zonal origin of the fibroblast.
  • DESIGN, SETTING, AND PARTICIPANTS: Human prostate fibroblasts from the peripheral (PZ), transition (TZ) and central (CZ) zones of radical prostatectomy specimens (n=13) were isolated and compared for their ability to promote androgen independence and metastatic progression in androgen-responsive PCa lymph node carcinoma of the prostate (LNCaP) cells in vivo.
  • INTERVENTIONS: By coinoculating marginally tumorigenic LNCaP cells with PZ or TZ and by altering host hormonal milieu, a series of tumorigenic and metastatic LNCaP epithelial sublines-P4, P4-2 (derivatives from interaction with PZ), T4, and T4-2 (derivatives from interaction with TZ)-were established and characterized.
  • MEASUREMENTS: In vivo and in vitro evaluation of induction of tumor growth and metastatic potential.
  • LNCaP sublines grew faster under anchorage-dependent and -independent conditions, expressed 1-12-fold more prostate-specific antigen in vitro than LNCaP cells, and gained metastatic potential;.
  • CONCLUSIONS: We demonstrate that prostate fibroblasts have growth inductive potential on PCa cells and affect their subsequent progression to castration resistance and development of a metastatic phenotype.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 European Association of Urology. All rights reserved.
  • [Cites] Trends Mol Med. 2007 Dec;13(12):535-41 [17981506.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):239-52 [19279573.001]
  • [Cites] Asian J Androl. 2009 Mar;11(2):176-82 [19122679.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11089-93 [17145848.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7682-90 [16140935.001]
  • [Cites] Br J Cancer. 1997;76(9):1134-8 [9365160.001]
  • [Cites] Br J Cancer. 1997;75(2):190-5 [9010025.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11802-7 [8876218.001]
  • [Cites] Semin Surg Oncol. 1995 Jan-Feb;11(1):9-22 [7754280.001]
  • [Cites] J Cell Biochem Suppl. 1994;19:267-9 [7823599.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2577-81 [8168083.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):318-24 [1568798.001]
  • [Cites] J Urol. 1992 Apr;147(4):1151-9 [1372662.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1179-87 [2732007.001]
  • [Cites] Anal Biochem. 1986 Nov 15;159(1):109-13 [3812988.001]
  • [Cites] Prostate. 1981;2(1):35-49 [7279811.001]
  • [Cites] J Reprod Med. 1976 Jul;17(1):25-8 [59808.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4109-18 [15483020.001]
  • [Cites] Urol Oncol. 2003 Sep-Oct;21(5):380-3 [14670549.001]
  • [Cites] Prostate. 2003 Nov 1;57(3):205-25 [14518029.001]
  • [Cites] Urology. 2003 Apr;61(4 Suppl 1):2-7 [12657354.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):772-8 [12548574.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):508-13 [12147437.001]
  • [Cites] Prostate. 2002 Mar 1;50(4):222-35 [11870800.001]
  • [Cites] J Urol. 2001 Dec;166(6):2472-83 [11696814.001]
  • [Cites] Cell. 2000 Nov 22;103(5):723-31 [11114329.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2) [10881018.001]
  • [CommentIn] Eur Urol. 2010 Jul;58(1):171-2 [19747764.001]
  • (PMID = 19747763.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082739; United States / NCI NIH HHS / CA / CA 098912; United States / NCI NIH HHS / CA / R01 CA122602; United States / NCI NIH HHS / CA / CA 119338; United States / NCI NIH HHS / CA / R01 CA108468; United States / NCI NIH HHS / CA / P20 CA132388; United States / NCI NIH HHS / CA / P01 CA098912-01A1; United States / NCI NIH HHS / CA / P01 CA098912; United States / NCI NIH HHS / CA / CA 108468; United States / NCI NIH HHS / CA / CA 082739; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / CA63341; United States / NCI NIH HHS / CA / CA63863; United States / NCI NIH HHS / CA / CA 132388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS142459; NLM/ PMC2889152
  •  go-up   go-down


58. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • The patient is now given 5-fluorouracil/cisplatin in addition to external radiotherapy (57.5 Gy) to the metastatic lymph node.
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. Li LZ, Zhou R, Xu HN, Moon L, Zhong T, Kim EJ, Qiao H, Reddy R, Leeper D, Chance B, Glickson JD: Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential. Proc Natl Acad Sci U S A; 2009 Apr 21;106(16):6608-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential.
  • Noninvasive or minimally invasive prediction of tumor metastatic potential would facilitate individualized cancer management.
  • Studies were performed on a panel of human melanoma xenografts that spanned the full range of metastatic potential measured by an in vivo lung colony assay and an in vitro membrane invasion culture system.
  • Three imaging methods potentially transferable to the clinic [dynamic contrast-enhanced (DCE) MRI, T(1(rho))-MRI, and low-temperature fluorescence imaging (measurable on biopsy specimens)] distinguished between relatively less metastatic and more metastatic human melanoma xenografts in nude mice.
  • K(trans) was significantly higher in the core of the least metastatic melanoma (A375P) than in the core of the most metastatic melanoma (C8161).
  • This study shows that a harsh microenvironment may promote melanoma metastasis and provides potential biomarkers of metastatic potential.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):480-91 [15667971.001]
  • [Cites] Magn Reson Med. 2004 Dec;52(6):1453-8 [15562469.001]
  • [Cites] NMR Biomed. 2005 May;18(3):173-85 [15578708.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5216-23 [16707446.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9029-33 [16740659.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):225-39 [17440684.001]
  • [Cites] Adv Exp Med Biol. 2007;599:67-78 [17727249.001]
  • [Cites] J Magn Reson Imaging. 2007 Dec;26(6):1607-17 [17968962.001]
  • [Cites] Magn Reson Med. 2008 Feb;59(2):326-35 [18228592.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):180-92 [18273037.001]
  • [Cites] Adv Exp Med Biol. 2009;645:247-53 [19227478.001]
  • [Cites] Int J Radiat Biol. 2000 May;76(5):589-605 [10866281.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Oct;20(10):1457-66 [11043908.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Magn Reson Med. 2001 Sep;46(3):565-72 [11550250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12479-84 [11606754.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Dec 14;289(4):813-8 [11735118.001]
  • [Cites] Breast Cancer. 2002;9(3):226-30 [12185334.001]
  • [Cites] Magn Reson Med. 2002 Sep;48(3):470-7 [12210911.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):430-50 [12353258.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Acad Radiol. 2003 Sep;10(9):963-8 [13678084.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1151-69 [14648563.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):147S-51S [15023742.001]
  • [Cites] J Magn Reson Imaging. 2004 Apr;19(4):403-9 [15065163.001]
  • [Cites] J Surg Oncol. 2004 Jul 1;86(4):224-35 [15221929.001]
  • [Cites] Magn Reson Med. 2004 Aug;52(2):248-57 [15282806.001]
  • [Cites] J Biol Chem. 1979 Jun 10;254(11):4764-71 [220260.001]
  • [Cites] J Natl Cancer Inst. 1984 Apr;72(4):913-7 [6584666.001]
  • [Cites] Anal Biochem. 1985 Aug 1;148(2):389-400 [4061818.001]
  • [Cites] Magn Reson Med. 1989 Dec;12(3):390-9 [2628687.001]
  • [Cites] Biotechniques. 1990 Sep;9(3):324-31 [2223075.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):227-37 [1671030.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 5;84(3):165-74 [1371813.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Mutat Res. 1998 Feb 26;398(1-2):19-26 [9626961.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Nature. 1955 Aug 6;176(4475):250-4 [13244669.001]
  • [Cites] J Biol Chem. 1958 Sep;233(3):736-9 [13575447.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):724-9 [15723402.001]
  • (PMID = 19366661.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA093372; United States / NCI NIH HHS / CA / P01-CA56690-09A2; United States / NCI NIH HHS / CA / R37 CA059702; United States / NHLBI NIH HHS / HL / R01 HL081185; United States / NCI NIH HHS / CA / P50-CA 093372; United States / NHLBI NIH HHS / HL / R01-HL081185; United States / NCI NIH HHS / CA / U54-CA105008; United States / NCI NIH HHS / CA / U01 CA105490; United States / NCRR NIH HHS / RR / P41-RR002305; United States / NCI NIH HHS / CA / UO1-CA105490; United States / NCI NIH HHS / CA / R01 CA059702; United States / NCI NIH HHS / CA / CA59702; United States / NCI NIH HHS / CA / P01 CA056690; United States / NCI NIH HHS / CA / U54 CA105008; United States / NCRR NIH HHS / RR / P41 RR002305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2672511
  •  go-up   go-down


60. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol; 2008 Dec;5(12):737-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
  • DIAGNOSIS: Stage IV M1b metastatic anal mucosal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Benzenesulfonates / therapeutic use. Melanoma / therapy. Pyridines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936790.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


61. Amano K, Ishibashi K, Nakada H, Okada N, Miyazaki T, Gonda T, Ishida H, Takahashi T: [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2025-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report].
  • We reported an elderly case of squamous cell carcinoma of the anal canal which showed complete response following radiotherapy alone.
  • An 86-year-old man complaining of anal bleeding and pain was admitted.
  • Biopsy revealed squamous cell carcinoma.
  • Magnetic resonance imaging did not show any metastatic lesions.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Provenzano PP, Eliceiri KW, Keely PJ: Shining new light on 3D cell motility and the metastatic process. Trends Cell Biol; 2009 Nov;19(11):638-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shining new light on 3D cell motility and the metastatic process.
  • Understanding tissue architecture and physical and chemical reciprocity between cells and their microenvironment provides vital insights into key events in cancer metastasis, such as cell migration through three-dimensional (3D) extracellular matrices.
  • Yet, many mechanistic details associated with metastasis remain elusive due to the difficulty of studying cancer cells in relevant 3D microenvironments.
  • Recently, optical imaging has facilitated the direct observation of single cells as they undertake fundamental steps in the metastatic processes.
  • Optical imaging is also providing novel 'optical biomarkers' with diagnostic potential that are linked to cell-motility pathways associated with metastasis, and these can to help guide new approaches to cancer diagnosis and therapy.
  • Here we present recent advances in one subclass of optical imaging of particular promise for cellular imaging - multiphoton microscopy - that can be used to improve the detection of malignant cells as well as advance our understanding of the cell biology of cancer metastasis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):89-117 [10933071.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jun;2(6):444-56 [11389468.001]
  • [Cites] Nat Med. 2001 Jul;7(7):864-8 [11433354.001]
  • [Cites] Biophys J. 2002 Jan;82(1 Pt 1):493-508 [11751336.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):682-7 [11830520.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):11-8 [11902581.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2125-30 [11929834.001]
  • [Cites] Biophys J. 2002 May;82(5):2811-25 [11964266.001]
  • [Cites] J Biomed Opt. 2002 Apr;7(2):205-14 [11966305.001]
  • [Cites] J Microsc. 2002 Apr;206(Pt 1):65-71 [12000564.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):266-76 [12001988.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):267-77 [12527751.001]
  • [Cites] Methods. 2003 Jan;29(1):97-109 [12543075.001]
  • [Cites] J Struct Biol. 2003 Jan;141(1):53-62 [12576020.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Science. 2003 Apr 4;300(5616):87-91 [12677058.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):122-32 [9234932.001]
  • [Cites] Biophys J. 1998 Oct;75(4):2015-24 [9746543.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6255-60 [10339574.001]
  • [Cites] Nat Biotechnol. 1999 Aug;17(8):763-7 [10429240.001]
  • [Cites] Science. 1962 Aug 17;137(3529):499-508 [13878016.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] Genes Dev. 2004 Dec 15;18(24):2998-3003 [15601818.001]
  • [Cites] FEBS Lett. 2005 Feb 7;579(4):927-32 [15680976.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] Biophys J. 2005 Feb;88(2):1224-37 [15531633.001]
  • [Cites] Biophys J. 2005 Feb;88(2):1377-86 [15533922.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 [15701700.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] BMC Biotechnol. 2005;5:14 [15910685.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5674-82 [15994941.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2005;95:17-56 [16080264.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2005;95:57-75 [16080265.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2005;95:143-75 [16080268.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051601 [16292949.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):905-9 [16299475.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):932-40 [16299478.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):941-50 [16299479.001]
  • [Cites] Biophys J. 2006 Jan 15;90(2):693-703 [16258040.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Science. 2006 Apr 14;312(5771):217-24 [16614209.001]
  • [Cites] J Biomed Opt. 2006 Mar-Apr;11(2):020502 [16674173.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):395-404 [16651380.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4429-40 [16547501.001]
  • [Cites] Curr Biol. 2006 Aug 8;16(15):1515-23 [16890527.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17137-42 [17088565.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] J Cell Biol. 2007 Jan 1;176(1):35-42 [17190792.001]
  • [Cites] BMC Med. 2006;4(1):38 [17190588.001]
  • [Cites] Biophys J. 2007 Mar 15;92(6):2212-22 [17172303.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):103-12 [17325340.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3505-11 [17440055.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):024014 [17477729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11760-5 [17601776.001]
  • [Cites] Dev Cell. 2008 Dec;15(6):813-28 [19081071.001]
  • [Cites] Exp Cell Res. 2009 Feb 1;315(3):396-410 [19041305.001]
  • [Cites] Med Phys. 2008 Dec;35(12):5758-67 [19175133.001]
  • [Cites] J Clin Invest. 2009 Feb;119(2):252-66 [19147981.001]
  • [Cites] Histol Histopathol. 2009 Apr;24(4):503-10 [19224453.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):357-70 [18766302.001]
  • [Cites] J Biophotonics. 2008 Mar;1(1):13-23 [19343631.001]
  • [Cites] J Cell Biol. 2009 Apr 6;185(1):11-9 [19332889.001]
  • [Cites] Cell Biochem Biophys. 2009;53(3):145-57 [19259625.001]
  • [Cites] Opt Lett. 2003 Jun 1;28(11):902-4 [12816240.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):711-9 [12844144.001]
  • [Cites] Opt Lett. 2003 Sep 1;28(17):1552-4 [12956376.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1369-77 [14595365.001]
  • [Cites] Photochem Photobiol. 2003 Nov;78(5):462-9 [14653577.001]
  • [Cites] Microsc Res Tech. 2004 Jan 1;63(1):18-22 [14677129.001]
  • [Cites] Microsc Res Tech. 2004 Jan 1;63(1):58-66 [14677134.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] J Neurophysiol. 2004 Apr;91(4):1908-12 [14668300.001]
  • [Cites] Science. 2004 Apr 30;304(5671):743-6 [15118165.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] Biosens Bioelectron. 2004 Oct 15;20(3):643-50 [15494250.001]
  • [Cites] Nature. 1985 Oct 24-30;317(6039):748-9 [4058582.001]
  • [Cites] J Cell Biol. 1987 Jul;105(1):41-8 [3112165.001]
  • [Cites] Science. 1990 Apr 6;248(4951):73-6 [2321027.001]
  • [Cites] Anal Biochem. 1992 May 1;202(2):316-30 [1519759.001]
  • [Cites] J Cell Sci. 1993 Jun;105 ( Pt 2):317-31 [8408268.001]
  • [Cites] Ann Biomed Eng. 1994 Jul-Aug;22(4):342-56 [7998680.001]
  • [Cites] J Cell Biochem. 2007 Aug 15;101(6):1338-54 [17471532.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Cell. 2007 Sep 7;130(5):784-95 [17803903.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):737-49 [17891189.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2048-57 [17932352.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Jan;24(1):64-9 [18043235.001]
  • [Cites] Nat Cell Biol. 2007 Dec;9(12):1392-400 [18037882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19494-9 [18042710.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):95-101 [18065276.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Lasers Surg Med. 2008 Apr;40(4):273-81 [18412229.001]
  • [Cites] Biophys J. 2008 Jun;94(11):4504-14 [18281387.001]
  • [Cites] BMC Med. 2008;6:11 [18442412.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-40 [18495291.001]
  • [Cites] Curr Opin Cell Biol. 2008 Oct;20(5):541-50 [18586481.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5497-510 [18794884.001]
  • [Cites] Opt Express. 2008 Oct 13;16(21):16431-41 [18852749.001]
  • [Cites] Am J Pathol. 2008 Nov;173(5):1551-65 [18845837.001]
  • [Cites] Trends Cell Biol. 2008 Nov;18(11):560-74 [18848450.001]
  • [Cites] Phys Med Biol. 2008 Dec 7;53(23):6641-52 [18997272.001]
  • [Cites] Biophys J. 2008 Dec;95(11):5374-84 [18775961.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054050 [19021430.001]
  • [Cites] Dis Model Mech. 2008 Sep-Oct;1(2-3):155-67; discussion 165 [19048079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11014-9 [12177437.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):683-93 [12209157.001]
  • [Cites] Curr Opin Neurobiol. 2002 Oct;12(5):593-601 [12367641.001]
  • [Cites] J Microsc. 2002 Oct;208(Pt 1):35-48 [12366596.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6278-88 [12414658.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7166-9 [12499251.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nat Med. 2003 Jan;9(1):123-8 [12514725.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] J Invest Dermatol. 2009 Jul;129(7):1752-8 [19177136.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):1909-19 [19528447.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Jul;10(7):445-57 [19546857.001]
  • [Cites] Nat Methods. 2009 Jul;6(7):511-2 [19525959.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(5):1680-95 [15713627.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Nat Med. 2003 Jun;9(6):796-800 [12754503.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7075-80 [12756303.001]
  • (PMID = 19819146.001).
  • [ISSN] 1879-3088
  • [Journal-full-title] Trends in cell biology
  • [ISO-abbreviation] Trends Cell Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076537; United States / NIBIB NIH HHS / EB / EB000184; United States / NCI NIH HHS / CA / R01 CA114462; United States / NIBIB NIH HHS / EB / R21 EB008811; United States / NCI NIH HHS / CA / R21 CA126635; United States / NCI NIH HHS / CA / R01 CA076537-11; United States / NIBIB NIH HHS / EB / EB008811-01A1; United States / NCI NIH HHS / CA / R01 CA142833; United States / NCI NIH HHS / CA / T32CA009681; United States / NCI NIH HHS / CA / R01 CA076537; United States / NCI NIH HHS / CA / CA076537-11; United States / NCI NIH HHS / CA / CA126635-01A1; United States / NIBIB NIH HHS / EB / R01 EB000184; United States / NIBIB NIH HHS / EB / R21 EB008811-01A1; United States / NCI NIH HHS / CA / R29 CA076537; United States / NCI NIH HHS / CA / R21 CA126635-01A1; United States / NCI NIH HHS / CA / T32 CA009681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 137
  • [Other-IDs] NLM/ NIHMS142781; NLM/ PMC2783928
  •  go-up   go-down


63. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, Demichelis F, Freeman MR: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res; 2009 Jul 1;69(13):5601-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.
  • Oncosomes have recently been described as membrane-derived microvesicles secreted by cancer cells, which transfer oncogenic signals and protein complexes across cell boundaries.
  • Here, we show the rapid formation and secretion of oncosomes from DU145 and LNCaP human prostate cancer cells.
  • Microvesicles shed from prostate cancer cells contained numerous signal transduction proteins and were capable of activating rapid phospho-tyrosine and Akt pathway signaling, and stimulating proliferation and migration, in recipient tumor cells.
  • Analysis of primary and metastatic human prostate tumors using 100K single nucleotide polymorphism arrays revealed a significantly higher frequency of deletion of the locus encoding DRF3 (DIAPH3) in metastatic tumors (P = 0.001) in comparison with organ-confined tumors.
  • Fluorescence in situ hybridization confirmed increased chromosomal loss of DIAPH3 in metastatic tumors in a different cohort of patients (P = 0.006).
  • These data suggest that microvesicles shed from prostate cancer cells can alter the tumor microenvironment in a manner that may promote disease progression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Mol Cell Proteomics. 2009 Jun;8(6):1192-205 [19204029.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3882-5 [11358800.001]
  • [Cites] Prostate. 2001 Nov 1;49(3):166-71 [11746261.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):172-80 [12115566.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):29108-15 [12034747.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39379-87 [12151408.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4599-608 [12446587.001]
  • [Cites] Curr Biol. 2003 Apr 1;13(7):534-45 [12676083.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):711-9 [12844144.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1775-9 [14657501.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29728-39 [15123714.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Microsc Res Tech. 1998 Nov 1;43(3):265-75 [9840805.001]
  • [Cites] FEBS Lett. 1999 Feb 26;445(2-3):431-9 [10094502.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] J Cell Sci. 2006 Jan 1;119(Pt 1):56-65 [16339170.001]
  • [Cites] Trends Cell Biol. 2006 Jan;16(1):5-10 [16325405.001]
  • [Cites] Cell. 2006 Jan 27;124(2):423-35 [16439214.001]
  • [Cites] Circ Res. 2006 Feb 3;98(2):245-53 [16357306.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5084-93 [16361249.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):195-202 [16546562.001]
  • [Cites] Urology. 2006 May;67(5):1016-21 [16698361.001]
  • [Cites] Proteomics. 2006 May;6(10):2982-90 [16622837.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3833-44 [16926192.001]
  • [Cites] J Cell Biol. 2006 Nov 6;175(3):477-90 [17088428.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):579-91 [17398099.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Cell Biol. 2007 Jul 2;178(1):23-30 [17606864.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6238-46 [17616681.001]
  • [Cites] J Cell Sci. 2007 Nov 1;120(Pt 21):3820-9 [17959630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):731-9 [18245473.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6232-40 [18174174.001]
  • [Cites] Nature. 2008 Mar 13;452(7184):230-3 [18337823.001]
  • [Cites] Exp Cell Res. 2008 Apr 15;314(7):1540-52 [18316075.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):619-24 [18425114.001]
  • [Cites] J Cell Biol. 2008 Jun 16;181(6):879-84 [18541702.001]
  • [Cites] BMC Cell Biol. 2008;9:30 [18534013.001]
  • [Cites] Cell Cycle. 2008 Jul 15;7(14):2257-67 [18635971.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27891-903 [18694941.001]
  • [Cites] Curr Biol. 2008 Oct 14;18(19):1456-65 [18835169.001]
  • [Cites] Trends Cell Biol. 2009 Feb;19(2):43-51 [19144520.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2210-8 [19258514.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9699-704 [11121407.001]
  • (PMID = 19549916.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112303-04; United States / NCI NIH HHS / CA / K08CA122833; United States / NCI NIH HHS / CA / CA97186; United States / PHS HHS / / R3747556; United States / NCI NIH HHS / CA / CA112303-04; United States / NCI NIH HHS / CA / P50 CA097186; United States / NCI NIH HHS / CA / P01 CA085859; United States / NCI NIH HHS / CA / P01CA085859; United States / NCI NIH HHS / CA / R01 CA112303; United States / NCI NIH HHS / CA / R01CA116337-01A1; United States / NIDDK NIH HHS / DK / P50 DK65298; United States / NCI NIH HHS / CA / K99 CA131472; United States / NIDDK NIH HHS / DK / P50 DK065298
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DIAPH3 protein, human; 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ NIHMS115499; NLM/ PMC2853876
  •  go-up   go-down


64. Diers AR, Dranka BP, Ricart KC, Oh JY, Johnson MS, Zhou F, Pallero MA, Bodenstine TM, Murphy-Ullrich JE, Welch DR, Landar A: Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy. Biochem J; 2010 Aug 15;430(1):69-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy.
  • Recently, a number of steps in the progression of metastatic disease have been shown to be regulated by redox signalling.
  • However, the therapeutic potential as well as the precise mechanisms of action of electrophilic lipids in cancer cells is poorly understood.
  • In the present study, we investigate the effect of the electrophilic prostaglandin 15d-PGJ2 (15-deoxy-Delta12,14-prostaglandin J2) on metastatic properties of breast cancer cells.
  • Taken together, the results of the present study suggest that electrophiles such as 15d-PGJ2 are potential anti-metastatic agents which exhibit specificity for migration and adhesion pathways at low concentrations where there are no observed effects on Keap1 or cytotoxicity.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14145-53 [15695504.001]
  • [Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):385-94 [15706085.001]
  • [Cites] J Am Soc Nephrol. 2006 Jan;17(1):89-98 [16291835.001]
  • [Cites] Biochem J. 2006 Feb 15;394(Pt 1):185-95 [16268779.001]
  • [Cites] Cancer Lett. 2006 May 8;236(1):133-41 [15979236.001]
  • [Cites] BMC Cancer. 2006;6:53 [16519808.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):1021-35 [16795079.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 3;349(4):1387-93 [16979589.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):246-54 [16412567.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1311-20 [17081101.001]
  • [Cites] Neurochem Res. 2006 Oct;31(10):1247-54 [17006759.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):163-80 [17084981.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jan;320(1):173-9 [17041009.001]
  • [Cites] Trends Neurosci. 2007 Jan;30(1):37-45 [17137643.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):695-705 [17160708.001]
  • [Cites] Biochemistry. 2007 Mar 13;46(10):2707-18 [17297918.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1091:548-70 [17341644.001]
  • [Cites] Biochem Pharmacol. 2007 Sep 1;74(5):690-701 [17640620.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1358-75 [17481747.001]
  • [Cites] Apoptosis. 2007 Nov;12(11):2101-14 [17786557.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10260-7 [17974967.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):609-17 [18097063.001]
  • [Cites] Chem Res Toxicol. 2008 Jan;21(1):117-28 [18052106.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(2):203-15 [17473980.001]
  • [Cites] Oncogene. 2008 May 8;27(21):3032-44 [18071320.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2203-11 [18645029.001]
  • [Cites] Expert Opin Ther Targets. 2008 Sep;12(9):1109-22 [18694378.001]
  • [Cites] J Biol Chem. 2008 Oct 31;283(44):30273-88 [18718914.001]
  • [Cites] Biochim Biophys Acta. 2008 Dec;1786(2):87-104 [18692117.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):35-49 [19169797.001]
  • [Cites] Int J Oncol. 2009 May;34(5):1363-72 [19360348.001]
  • [Cites] Neurochem Res. 2009 Aug;34(8):1479-90 [19263218.001]
  • [Cites] Free Radic Biol Med. 2009 Aug 1;47(3):201-12 [19446632.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):255-61 [11208866.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 15;31(12):1624-32 [11744337.001]
  • [Cites] J Immunol. 2002 Apr 1;168(7):3563-9 [11907120.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):573-83 [11955950.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20453-60 [11923291.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jan;304(1):349-55 [12490611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4772-7 [12684535.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(1):63-74 [12779083.001]
  • [Cites] J Clin Invest. 2003 Sep;112(6):828-30 [12975467.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2149-53 [14562367.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1381-91 [14555212.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):31-8 [14715242.001]
  • [Cites] Biochem Soc Trans. 2004 Feb;32(Pt 1):151-5 [14748737.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):373-82 [14616092.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12769-76 [14688256.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):501-12 [15130277.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2569-77 [15128872.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1890-909 [15203104.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 Jul;4(4):379-87 [15281909.001]
  • [Cites] Exp Cell Res. 2004 Sep 10;299(1):236-47 [15302590.001]
  • [Cites] Free Radic Biol Med. 2004 Sep 15;37(6):768-84 [15304253.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] J Cell Biol. 1989 Sep;109(3):1309-19 [2768342.001]
  • [Cites] Biochem J. 1990 Apr 15;267(2):453-9 [2334404.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):147-55 [7505391.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355-9 [8041794.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):12953-6 [7768881.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):81-92 [15485993.001]
  • [Cites] Clin Immunol. 2005 Feb;114(2):100-9 [15639643.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):135-45 [15907837.001]
  • (PMID = 20536428.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087728; United States / NHLBI NIH HHS / HL / HL079644-01A2; United States / NCI NIH HHS / CA / R01 CA87728; United States / NHLBI NIH HHS / HL / R01 HL079644-01A2; United States / NHLBI NIH HHS / HL / T32 HL007918-13; United States / NHLBI NIH HHS / HL / T32 HL007918; United States / NHLBI NIH HHS / HL / HL007918-13; United States / NHLBI NIH HHS / HL / R01 HL079644; United States / NCI NIH HHS / CA / R01 CA087728-09S1; United States / NCI NIH HHS / CA / CA087728-09S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 15-deoxy-delta(12,14)-prostaglandin J2; 0 / Actins; 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents; 0 / Cytoskeletal Proteins; 0 / Keap1 protein, mouse; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Ptk2 protein, mouse; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; RXY07S6CZ2 / Prostaglandin D2
  • [Other-IDs] NLM/ NIHMS231654; NLM/ PMC2963584
  •  go-up   go-down


65. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P: Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev; 2008 Nov;34(7):629-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
  • Metastatic bone disease alters bone homeostasis, resulting in reduced bone integrity and, consequently, increased skeletal complications.
  • MATERIALS AND METHODS: Data for this review were identified by searches of PubMed, and references from relevant articles using the search terms "bone markers" or individual bone marker nomenclature, "cancer," and "metastases."
  • CONCLUSIONS: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Bone Resorption / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1996 Aug;17(4):333-68 [8854049.001]
  • [Cites] Clin Chem. 1997 Sep;43(9):1570-6 [9299935.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3743-50 [9345061.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Bone. 1998 Jan;22(1):73-8 [9437516.001]
  • [Cites] Ann Oncol. 1997 Dec;8(12):1243-50 [9496390.001]
  • [Cites] Clin Chem. 1998 Mar;44(3):578-85 [9510865.001]
  • [Cites] J Endocrinol. 1998 Oct;159(1):127-31 [9795350.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):16-22 [10073146.001]
  • [Cites] Clin Chem. 1999 Aug;45(8 Pt 2):1359-68 [10430819.001]
  • [Cites] Kaohsiung J Med Sci. 1999 Aug;15(8):452-60 [10518361.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):59-69 [15632381.001]
  • [Cites] J Pharm Biomed Anal. 2005 Feb 7;37(1):171-6 [15664758.001]
  • [Cites] Acta Oncol. 2007;46(2):221-9 [17453373.001]
  • [Cites] Osteoporos Int. 2007 Nov;18(11):1515-23 [17483864.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1035-43 [17914073.001]
  • [Cites] J Thorac Oncol. 2008 Mar;3(3):228-36 [18317064.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):193-201 [18459173.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31 [16105967.001]
  • [Cites] J Chemother. 2005 Oct;17(5):555-9 [16323446.001]
  • [Cites] J Am Soc Nephrol. 2006 Jan;17(1):262-70 [16280472.001]
  • [Cites] Urol Int. 2006;76(1):67-71 [16401924.001]
  • [Cites] J Bone Miner Res. 2006 Feb;21(2):292-9 [16418785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):32-8 [16434583.001]
  • [Cites] Prostate. 2006 Apr 1;66(5):503-13 [16372331.001]
  • [Cites] J Endocrinol Invest. 2005;28(10 Suppl):14-22 [16550717.001]
  • [Cites] Bone. 2000 Apr;26(4):367-73 [10719280.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):858-64 [10732759.001]
  • [Cites] Osteoporos Int. 2000;11(6):481-5 [10982162.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):344-51 [11161399.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1721-2 [11514416.001]
  • [Cites] Endocrinology. 2001 Dec;142(12):5050-5 [11713196.001]
  • [Cites] Scand J Clin Lab Invest. 2001;61(7):513-21 [11763409.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Bone. 2002 Jan;30(1):307-13 [11792602.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):850-6 [11821470.001]
  • [Cites] Bone. 2002 Mar;30(3):502-8 [11882465.001]
  • [Cites] Clin Chem. 2005 Mar;51(3):618-28 [15650032.001]
  • [Cites] Blood Rev. 2005 May;19(3):125-42 [15748961.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):841-3 [15781576.001]
  • [Cites] Clin Calcium. 2005 May;15(5):741-6 [15876734.001]
  • [Cites] Clin Calcium. 2005 Jul;15(7):17-22 [15995291.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1223-31 [15928069.001]
  • [Cites] Ned Tijdschr Tandheelkd. 2005 Jul;112(7):258-63 [16047964.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4925-35 [15983391.001]
  • [Cites] J Bone Miner Res. 2005 Sep;20(9):1669-79 [16059638.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5765-8 [16046585.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1969-76 [16079895.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1351-7 [16596210.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):399-404 [16480429.001]
  • [Cites] N Engl J Med. 2006 May 25;354(21):2250-61 [16723616.001]
  • [Cites] Ann N Y Acad Sci. 2006 Apr;1068:180-6 [16831917.001]
  • [Cites] Oncologist. 2006;11 Suppl 1:13-9 [16971735.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4895-900 [17001071.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):688-92 [17107351.001]
  • [Cites] BMC Musculoskelet Disord. 2007;8:13 [17316428.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2353-9 [11981007.001]
  • [Cites] Cancer. 2002 May 15;94(10):2521-33 [12173317.001]
  • [Cites] Calcif Tissue Int. 2002 Jul;71(1):20-5 [12073156.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):235-42 [12542480.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):455-7 [12845688.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1064-9 [12689925.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3047-51 [12912955.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1735-44 [14534891.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5059-75 [14602728.001]
  • [Cites] Acta Biochim Pol. 2003;50(4):1019-38 [14739992.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):455-9 [14998848.001]
  • [Cites] J Pharm Biomed Anal. 2004 Mar 1;34(4):827-32 [15019061.001]
  • [Cites] Clin Chem. 2004 May;50(5):883-90 [15016726.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):783-91 [15252851.001]
  • [Cites] Biochem J. 1991 Mar 1;274 ( Pt 2):513-20 [2006915.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):178-82 [8325940.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):14853-6 [8195113.001]
  • [Cites] Clin Chem. 1995 Oct;41(10):1489-94 [7586522.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1089-95 [8624269.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2347-54 [8641185.001]
  • [Cites] Osteoporos Int. 1995;5(6):472-7 [8695971.001]
  • (PMID = 18579314.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10048; United States / NCI NIH HHS / CA / K24 CA121990; United States / NCI NIH HHS / CA / K24 CA121990-02; United States / NCI NIH HHS / CA / K24 CA121990-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Osteoprotegerin; 0 / Procollagen; 0 / Sialoglycoproteins; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  • [Number-of-references] 90
  • [Other-IDs] NLM/ NIHMS204599; NLM/ PMC3090688
  •  go-up   go-down


66. Liu L, Cao Y, Tan A, Liao C, Mo Z, Gao F: Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials. Colorectal Dis; 2010 May;12(5):399-406
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
  • PURPOSE: A meta-analysis was performed to assess the efficacy and safety of cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508512.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


67. Kuga Y, Tanaka T, Arita M, Usui Y, Okanobu H, Numata Y, Miwata T, Yoshimi S, Murakami E, Moriya T, Ohya T, Nishida T: [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1923-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma].
  • We report a case of left inguinal lymph node metastasis of anal canal carcinoma, treated effectively with chemotherapy consisting of S-1 and CDDP combined with radiotherapy.
  • In February 2006, a 76-year-old woman underwent resection of a tumor diagnosed as squamous cell carcinoma of the anal canal.
  • Biopsy was performed, and specimens were shown to include squamous cell carcinoma cells.
  • The metastatic tumor in the lymph node responded well to the treatment and decreased remarkably in size by December 2007.
  • Chemotherapy consisting of S-1 and CDDP concurrent with radiotherapy maybe effective for treating metastatic lymph node metastasis of anal canal carcinoma.
  • [MeSH-major] Anal Canal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis
  • [MeSH-minor] Administration, Oral. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Humans. Inguinal Canal. Injections, Intravenous. Oxonic Acid / administration & dosage. Radiotherapy Dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K: Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res; 2009;11(3):R39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.
  • INTRODUCTION: We evaluated whether CK19, one of the main cytoskeleton proteins of epithelial cells, is released as full-length protein from viable tumor cells and whether this property is relevant for metastatic progression in breast cancer patients.
  • METHODS: EPISPOT (EPithelial ImmunoSPOT) assays were performed to analyze the release of full-length CK19 by carcinoma cells of various origins, and the sequence of CK19 was analyzed with mass spectrometry.
  • CK19-EPISPOT was used to detect disseminated tumor cells in bone marrow (BM) of 45 breast cancer patients who were then followed up over a median of 6 years.
  • RESULTS: CK19 was expressed and released by colorectal (HT-29, HCT116, Caco-2) and breast (MCF-7, SKBR3, and MDA-MB-231) cancer cell lines.
  • CK19-releasing cells (RCs) were detectable in BM of 44% to 70% of breast cancer patients.
  • CONCLUSIONS: Full-length CK19 is released by viable epithelial tumor cells, and CK19-RCs might constitute a biologically active subset of breast cancer cells with high metastatic properties.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):110-22 [11792552.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(1):219-21 [18853248.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] J Cell Biochem. 2002;85(4):670-7 [11968007.001]
  • [Cites] Anal Chem. 2003 Feb 1;75(3):663-70 [12585499.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:33-44 [14521514.001]
  • [Cites] Mol Cell Proteomics. 2004 Jan;3(1):73-81 [14593079.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] Cancer Detect Prev. 1983;6(1-2):41-50 [6883392.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):109-21 [6361139.001]
  • [Cites] J Submicrosc Cytol. 1985 Jul;17(3):357-61 [2410624.001]
  • [Cites] Can J Biochem Cell Biol. 1985 Jun;63(6):680-90 [2412674.001]
  • [Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2241-3 [10928185.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3117-22 [10955792.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):468-73 [11251967.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1890-5 [11280743.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):31-7 [11743639.001]
  • [Cites] Eur J Cell Biol. 1988 Dec;47(2):300-19 [2468493.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):61-6 [7677981.001]
  • [Cites] J Virol. 1994 Aug;68(8):4857-61 [8035484.001]
  • [Cites] Annu Rev Biochem. 1994;63:345-82 [7979242.001]
  • [Cites] Eur J Biochem. 1995 Jul 15;231(2):475-85 [7543411.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1035-9 [7489359.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33197-203 [9407108.001]
  • [Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]
  • [Cites] J Immunol Methods. 2005 Apr;299(1-2):177-88 [15914200.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1538-41 [16040853.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]
  • [Cites] Nature. 2006 May 18;441(7091):362-5 [16710422.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5 [17079488.001]
  • [Cites] Clin Chem. 2007 Mar;53(3):537-9 [17327507.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):329-40 [18404148.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3646-50 [18559576.001]
  • [Cites] Methods Mol Biol. 2008;484:97-109 [18592175.001]
  • [Cites] J Proteome Res. 2008 Jul;7(7):3060-3 [18494517.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5013-21 [18698019.001]
  • [Cites] J Natl Cancer Inst. 2009 Jan 7;101(1):61-6 [19116383.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):267-8 [19383302.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 [19399023.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):693-706 [11914275.001]
  • (PMID = 19549321.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epitopes; 0 / Keratin-19
  • [Other-IDs] NLM/ PMC2716508
  •  go-up   go-down


69. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL: Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int; 2009 Jun;103(12):1636-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
  • OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer.
  • Secondary endpoints included pharmacokinetics, toxicity analysis and overall survival.
  • CONCLUSIONS: Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2178-85 [18445842.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5472-80 [16061863.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1688-94 [16006586.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] Urology. 2006 Jun;67(6):1235-40 [16765185.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):556-63 [17577218.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1480-5 [18040273.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):209-14 [18172272.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):521-6 [18085595.001]
  • [Cites] J Pharm Biomed Anal. 2008 Jan 22;46(2):362-7 [18309574.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1148-59 [18309951.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):746-51 [18056648.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • (PMID = 19154507.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006538-15
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 33515-09-2 / Gonadotropin-Releasing Hormone; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / raf Kinases
  • [Other-IDs] NLM/ NIHMS164017; NLM/ PMC2818665
  •  go-up   go-down


70. Tsuruta Y, Matsumoto M, Inoue H, Munemura S, Yamano S, Iguchi H: Determination of N-ethylglycine in urine of cancer patients with metastatic bone disease by HPLC using 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride as a fluorescent labeling reagent. Anal Sci; 2008 Dec;24(12):1629-31
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of N-ethylglycine in urine of cancer patients with metastatic bone disease by HPLC using 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride as a fluorescent labeling reagent.
  • The concentration of N-ethylglycine in urine of cancer patients with metastatic bone disease was 11.3 +/- 22.0 nmol/mg creatinine, and that of normal subject was 0.4 +/- 0.4 nmol/mg creatinine.
  • [MeSH-major] Bone Neoplasms / secondary. Bone Neoplasms / urine. Fluorescent Dyes / chemistry. N-substituted Glycines / urine. Phthalimides / chemistry

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075476.001).
  • [ISSN] 1348-2246
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride; 0 / Fluorescent Dyes; 0 / N-ethylglycine; 0 / N-substituted Glycines; 0 / Phthalimides; 643-79-8 / o-Phthalaldehyde
  •  go-up   go-down


71. Ivanović V, Dedović-Tanić N, Milovanović Z, Lukić S, Nikolić S, Baltić V, Stojiljković B, Budisin N, Savovski K, Demajo M, Dimitrijević B: Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source. Anal Quant Cytol Histol; 2009 Oct;31(5):288-95
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source.
  • OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGFbeta1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC.
  • RESULTS: The data indicated a highly significant (r = 0.973054) positive linear correlation between the TGFbeta1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT.
  • This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes.
  • CONCLUSION: Our data provide for the first time suggestive evidence that the TGFbeta1 level in cytoplasmic extracts of metastatic ALNTs may be a promising biomarker of invasiveness for BC patients.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701096.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1
  •  go-up   go-down


72. Okada F, Shionoya H, Kobayashi M, Kobayashi T, Tazawa H, Onuma K, Iuchi Y, Matsubara N, Ijichi T, Dugas B, Hosokawa M: Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase. Br J Cancer; 2006 Mar 27;94(6):854-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase.
  • Arising tumour cells in gliadin and saline groups acquired metastatic phenotype, but those in oxykine group showed reduced metastatic ability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1978 Sep;38(9):2759-62 [679181.001]
  • [Cites] FEBS J. 2005 Sep;272(17):4431-8 [16128812.001]
  • [Cites] N Engl J Med. 1980 Jul 3;303(1):27-34 [6246431.001]
  • [Cites] Exp Eye Res. 1981 Dec;33(6):651-61 [6797833.001]
  • [Cites] Gene Ther. 2001 Jan;8(2):149-56 [11313784.001]
  • [Cites] Gut. 2003 Feb;52(2):218-23 [12524403.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):424-32 [12538496.001]
  • [Cites] Redox Rep. 2002;7(6):357-68 [12625943.001]
  • [Cites] Nat Med. 2003 Jun;9(6):750-5 [12730689.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] J Ethnopharmacol. 2004 Sep;94(1):67-75 [15261965.001]
  • [Cites] J Biol Chem. 1969 Nov 25;244(22):6049-55 [5389100.001]
  • [Cites] Anal Biochem. 1971 Nov;44(1):276-87 [4943714.001]
  • [Cites] J Clin Invest. 1973 Mar;52(3):741-4 [4346473.001]
  • [Cites] Cancer Res. 1982 Feb;42(2):609-17 [6275983.001]
  • [Cites] Int J Cancer. 1984 Jun 15;33(6):783-6 [6329968.001]
  • [Cites] Med Biol. 1984;62(5):285-9 [6530902.001]
  • [Cites] Biochem Biophys Res Commun. 1985 May 31;129(1):300-5 [2988549.001]
  • [Cites] J Biochem. 1986 May;99(5):1289-98 [3519601.001]
  • [Cites] Cancer Lett. 1986 Jul;32(1):7-13 [3017547.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):338-42 [2434441.001]
  • [Cites] J Biol Chem. 1988 May 15;263(14):6884-92 [3129432.001]
  • [Cites] Mol Cell Biochem. 1988 Dec;84(2):147-53 [3068520.001]
  • [Cites] Mol Cell Biochem. 1988 Dec;84(2):189-98 [3231222.001]
  • [Cites] Am J Pathol. 1989 Apr;134(4):787-96 [2705506.001]
  • [Cites] Free Radic Biol Med. 1989;6(4):379-84 [2540070.001]
  • [Cites] J Cell Physiol. 1989 May;139(2):370-6 [2715192.001]
  • [Cites] Science. 1989 May 26;244(4907):974-6 [2543070.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2538-42 [2317833.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):939-43 [1988135.001]
  • [Cites] Cancer Lett. 1991 May 24;57(3):199-202 [2032208.001]
  • [Cites] J Biochem. 1991 Mar;109(3):477-85 [1880134.001]
  • [Cites] Free Radic Biol Med. 1992;12(4):281-6 [1315710.001]
  • [Cites] Adv Clin Chem. 1992;29:1-59 [1585847.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):476-80 [1592538.001]
  • [Cites] J Lab Clin Med. 1992 Jun;119(6):598-620 [1593209.001]
  • [Cites] Cancer Lett. 1992 Mar 15;62(3):211-5 [1596865.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):635-9 [1419599.001]
  • [Cites] Mol Carcinog. 1992;6(4):238-42 [1485915.001]
  • [Cites] Biofactors. 2005;23(2):85-95 [16179750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Mol Aspects Med. 1993;14(3):253-8 [8264340.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):287-92 [8157366.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4261-5 [8044768.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):233-8 [8054271.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12808-12 [7809125.001]
  • [Cites] Free Radic Biol Med. 1995 Apr;18(4):775-94 [7750801.001]
  • [Cites] Oncogene. 1995 May 18;10(10):1989-2000 [7761099.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6210-4 [8521415.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2864-71 [8665527.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3192-5 [8764104.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):481-90 [9053845.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Histol Histopathol. 1997 Apr;12(2):525-35 [9151141.001]
  • [Cites] Cancer Immunol Immunother. 1998 Aug;46(6):338-44 [9756418.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):377-85 [10027302.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25869-76 [10464329.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Free Radic Res. 2004 Sep;38(9):927-32 [15621710.001]
  • [Cites] Cancer Res. 1979 Apr;39(4):1141-9 [217531.001]
  • (PMID = 16508635.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC2361372
  •  go-up   go-down


73. Cao Y, Liao C, Tan A, Liu L, Mo Z, Gao F: Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials. Colorectal Dis; 2010 Jan;12(1):16-23
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
  • OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of capecitabine plus oxaliplatin vs fluorouracil (FU) plus oxaliplatin as first line treatment for metastatic or advanced colorectal cancer.
  • CONCLUSION: The effect of capecitabine plus oxaliplatin regimen is similar to FU plus oxaliplatin regimen as first line treatment for metastatic colorectal cancer, but it offers advantages of simplicity and convenience to administer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220378.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Goldfarb Y, Benish M, Rosenne E, Melamed R, Levi B, Glasner A, Ben-Eliyahu S: CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination. J Immunother; 2009 Apr;32(3):280-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination.
  • Suppression of natural killer (NK) cell activity is common after stress, has been reported to predict malignant recurrence in cancer patients, and was shown to underlie metastatic dissemination in animal models.
  • In the current study using Fisher 344 rats, we examined the prophylactic use of different regimens of type-C CpG oligodeoxynucleotides (CpG-C ODN) on NK activity and metastatic dissemination in the context of pharmacologic stress (using metaproterenol for beta-adrenoceptor stimulation).
  • Depletion of NK cells revealed their key role in improving baseline levels of resistance to metastatic dissemination after CpG-C ODN administration.
  • Overall, prophylactic CpG-C ODN treatment can improve immunocompetence and potentially reduce metastatic dissemination, especially in clinical settings characterized by enhanced sympathetic stress responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5429-32 [10554011.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):4067-74 [18322216.001]
  • [Cites] J Exp Med. 1989 Apr 1;169(4):1373-89 [2466943.001]
  • [Cites] J Clin Lab Anal. 1990;4(4):274-82 [2391582.001]
  • [Cites] Eur J Clin Invest. 1992 Oct;22 Suppl 1:30-6 [1333965.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):2042-52 [18398660.001]
  • [Cites] Breast Cancer Res Treat. 2000 Apr;60(3):227-34 [10930110.001]
  • [Cites] Pharmacol Rev. 2000 Dec;52(4):595-638 [11121511.001]
  • [Cites] Neuroimmunomodulation. 2000;8(3):154-64 [11124582.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Eur J Immunol. 2001 Jun;31(6):1900-9 [11433387.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5523-8 [11454702.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1141-4 [11466327.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42 [11470918.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40 [11763350.001]
  • [Cites] Annu Rev Immunol. 2002;20:709-60 [11861616.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17 Suppl 1:S27-36 [12615183.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 May;28(5):541-5 [12707008.001]
  • [Cites] J Leukoc Biol. 2003 Jun;73(6):781-92 [12773511.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):254-60 [12892809.001]
  • [Cites] Dig Surg. 2003;20(5):445-51 [12900537.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):972-92 [14527919.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10116-21 [15218108.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):395-402 [15245441.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):1647-57 [15265893.001]
  • [Cites] Arch Int Pharmacodyn Ther. 1976 Sep;223(1):71-87 [999404.001]
  • [Cites] J Immunol Methods. 1981;42(3):305-18 [7026679.001]
  • [Cites] Nat Med. 1996 Apr;2(4):457-60 [8597957.001]
  • [Cites] J Immunol. 1996 Sep 1;157(5):2116-22 [8757335.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1900-7 [8980388.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3251-8 [9531281.001]
  • [Cites] Nat Med. 1999 Apr;5(4):405-11 [10202929.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):727-34 [15634892.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):114-26 [15664784.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):63-72 [15699627.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(4):508-15 [15737554.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):739-46 [15696196.001]
  • [Cites] Curr Pharm Des. 2005;11(22):2889-907 [16101444.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Eur J Immunol. 2006 Apr;36(4):961-7 [16525994.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jun;5(6):471-84 [16763660.001]
  • [Cites] J Control Release. 2006 Oct 10;115(2):226-33 [16996162.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3851-8 [16873676.001]
  • [Cites] Vet Immunol Immunopathol. 2007 Jan 15;115(1-2):24-34 [17067685.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):395-408 [17240115.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):503-13 [17293081.001]
  • [Cites] Immunol Res. 2007;39(1-3):15-21 [17917052.001]
  • [Cites] Vaccine. 2007 Nov 28;25(49):8241-56 [17980936.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):789-97 [18049330.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):211-23 [17431763.001]
  • [Cites] J Neuroimmunol. 2008 Jan;193(1-2):113-9 [18037507.001]
  • [Cites] J Immunol. 1985 Apr;134(4):2783-9 [3871818.001]
  • (PMID = 19242372.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125456; United States / NCI NIH HHS / CA / CA125456-01A1; United States / NCI NIH HHS / CA / R01 CA125456-02; United States / NCI NIH HHS / CA / CA125456-02; United States / NCI NIH HHS / CA / R01 CA125456; United States / NCI NIH HHS / CA / R01 CA125456-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / CPG-oligonucleotide; 0 / Oligodeoxyribonucleotides; 0 / Receptors, Adrenergic, beta; 53QOG569E0 / Metaproterenol
  • [Other-IDs] NLM/ NIHMS126415; NLM/ PMC2738855
  •  go-up   go-down


75. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, Ross BD: A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia; 2007 Dec;9(12):1003-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
  • Prostate cancer (PCa) is the most commonly diagnosed cancer in American men with a subset inevitably presenting with metastatic disease to the bone.
  • A well-recognized limitation in evaluating new treatments for metastatic PCa is the inability to use imaging to objectively assess response therapy.
  • In this study, we evaluated the feasibility of clinically translating the functional diffusion map (fDM) imaging biomarker for quantifying the spatiotemporal effects of bone tumor response in a patient treated for metastatic PCa with bone metastases.
  • Three metastatic lesions were identified for fDM analysis, all of which all demonstrated an early increase in diffusion values at 2 weeks, which increased further at 8 weeks post-treatment initiation.
  • Thus, the fDM imaging biomarker may provide a quantifiable therapeutic endpoint to assess response in patients with metastatic bone cancer.

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Nucl Med. 2007 Jun;21(4):209-15 [17581719.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1622-35 [17515386.001]
  • [Cites] Br J Cancer. 1978 Jul;38(1):201 [687517.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):61-4 [8554985.001]
  • [Cites] Cancer Gene Ther. 1998 Mar-Apr;5(2):101-9 [9570301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7012-7 [9618530.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3791-9 [9731486.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):195-206 [9873906.001]
  • [Cites] Clin Nucl Med. 1999 Jan;24(1):15-20 [9890487.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1457-66 [9815831.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7852-9 [15585617.001]
  • [Cites] MAGMA. 2004 Dec;17(3-6):249-59 [15580371.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):831-7 [15720810.001]
  • [Cites] Semin Nucl Med. 2005 Apr;35(2):135-42 [15765376.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9 [15805192.001]
  • [Cites] Neoplasia. 2005 May;7(5):475-85 [15967100.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5223-32 [16033840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] Gene Ther. 2006 Jan;13(2):127-37 [16163381.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9 [10677530.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1005-10 [10871748.001]
  • [Cites] Neoplasia. 1999 Jun;1(2):113-7 [10933044.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36 [11121466.001]
  • [Cites] Semin Nucl Med. 2001 Jul;31(3):206-11 [11430527.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):255-62 [11988845.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):581-7 [12813138.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):336-43 [12926229.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2942-53 [15254062.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):292-8 [856236.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4687-92 [16651420.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):259-67 [16756718.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3984-90 [16921051.001]
  • [Cites] Eur Radiol. 2006 Dec;16(12):2637-43 [16909220.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Pediatr Radiol. 2006 Dec;36(12):1306-11 [17031633.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):443-50 [17255264.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1488-92 [17332293.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1839-46 [17363540.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3524-8 [17440058.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2351-61 [17786228.001]
  • (PMID = 18084607.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32CA009357; United States / NCI NIH HHS / CA / P01 CA087634; United States / NCI NIH HHS / CA / P01CA87634; United States / NCI NIH HHS / CA / P50CA93990; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / P01CA093900; United States / NCI NIH HHS / CA / T32 CA009357; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / P01CA85878; United States / NCI NIH HHS / CA / P50 CA093990; United States / NCI NIH HHS / CA / P01 CA093900
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2134897
  • [Keywords] NOTNLM ; Metastatic prostate cancer / androgen deprivation therapy / diffusion MRI / functional diffusion map / imaging biomarker
  •  go-up   go-down


76. Prien JM, Huysentruyt LC, Ashline DJ, Lapadula AJ, Seyfried TN, Reinhold VN: Differentiating N-linked glycan structural isomers in metastatic and nonmetastatic tumor cells using sequential mass spectrometry. Glycobiology; 2008 May;18(5):353-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiating N-linked glycan structural isomers in metastatic and nonmetastatic tumor cells using sequential mass spectrometry.
  • In an effort to understand the role of molecular glycosylation in cancer a murine model has been used to characterize and fingerprint malignancies in established cell lines that manifest all the hallmarks of metastatic disease: spontaneous development, local invasion, intravasation, immune system survival, extravasation, and secondary tumor formation involving liver, kidney, spleen, lung, and brain.
  • Using astrocyte cell controls, we compared N-linked glycosylation from a nonmetastatic brain tumor cell line and two different metastatic brain tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glycoconj J. 2004;20(1):71-8 [14993838.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):475-82 [3335015.001]
  • [Cites] Development. 1991 Aug;112(4):959-70 [1718678.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):799-814 [7678837.001]
  • [Cites] J Gastroenterol. 1994 Apr;29(2):129-38 [7912139.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4425-31 [7545541.001]
  • [Cites] J Neurochem. 1996 Feb;66(2):834-44 [8592159.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3238-46 [8621726.001]
  • [Cites] Eur J Biochem. 1998 Feb 1;251(3):691-703 [9490042.001]
  • [Cites] FEMS Immunol Med Microbiol. 2005 Aug 1;45(2):171-82 [16051069.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6250-62 [16194086.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6263-70 [16194087.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6271-9 [16194088.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):348-51 [16455543.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12776-85 [16522637.001]
  • [Cites] EMBO Rep. 2006 Jun;7(6):599-604 [16741504.001]
  • [Cites] Nat Med. 2006 Aug;12(8):895-904 [16892035.001]
  • [Cites] Glycobiology. 2006 Sep;16(9):874-90 [16769777.001]
  • [Cites] Cell. 2007 Apr 6;129(1):123-34 [17418791.001]
  • [Cites] Anal Chem. 2007 May 15;79(10):3830-42 [17397137.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):73-84 [18398829.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):285-92 [11461091.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1778-82 [4027909.001]
  • (PMID = 18256178.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016459; United States / NCRR NIH HHS / RR / RR-16459; United States / NIGMS NIH HHS / GM / GM054045-11; United States / NIGMS NIH HHS / GM / R01 GM054045; United States / NIGMS NIH HHS / GM / R01-GM54045; United States / NIGMS NIH HHS / GM / R01 GM054045-11
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Polysaccharides
  • [Other-IDs] NLM/ NIHMS54817; NLM/ PMC2652488
  •  go-up   go-down


77. Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, Glynne-Jones R: Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):715-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?
  • PURPOSE: To describe the MRI appearances of squamous cell carcinoma of the anal canal before and after chemoradiation and to assess whether MRI features predict for clinical outcome.
  • METHODS AND MATERIALS: Thirty-five patients (15 male, 20 female; mean age 60.8 years) with histologically proven squamous cell cancer of the anal canal underwent MRI before and 6-8 weeks after definitive chemoradiation.
  • At a median follow-up of 33.5 months, 25 patients (71.4%) remained disease-free; 10 patients (28.6%) had locoregional or metastatic disease.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Anal Canal / pathology. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171812.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
  • These findings indicated that the core structures of O-glycans are profoundly involved in the metastatic capacity of cancer cells.
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


79. Visigalli D, Palmieri D, Strangio A, Astigiano S, Barbieri O, Casartelli G, Zicca A, Manduca P: The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts. BMC Cancer; 2009;9:59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts.
  • BACKGROUND: The COOH terminal peptide of Pro-collagen type I (PICP, also called C3) is chemotactic for endothelial melanoma and breast cancer cells.
  • PICP induces the expression of Metalloproteinases-2 and -9, of Vascular endothelial growth factor and of the chemokine CXCL-12 receptor CXCR4 in MDA MB231 breast carcinoma cells in vitro.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Diagn. 1999 Sep;4(3):169-83 [10553018.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32658-63 [10924500.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(1):69-77 [12000221.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3639-47 [12441353.001]
  • [Cites] Cell. 2003 Jul 25;114(2):171-80 [12887919.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5230-3 [14500350.001]
  • [Cites] Eur J Cell Biol. 2003 Nov;82(11):539-48 [14703010.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):86-9 [7507651.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5517-20 [9407961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13221-6 [9789069.001]
  • [Cites] J Pathol. 1998 Nov;186(3):262-8 [10211114.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95 [18843117.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Oncogene. 2005 Sep 1;24(38):5850-7 [16007210.001]
  • [Cites] Breast. 2005 Oct;14(5):360-7 [16216737.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):30-41 [16046252.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):283-90 [16924371.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2026-9 [16671092.001]
  • [Cites] Cancer Lett. 2007 Aug 8;253(1):34-42 [17306924.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):1987-94 [17719831.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1659-65 [17725805.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):57-66 [18058195.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2050-6 [18172859.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):241-2 [18371356.001]
  • [Cites] Hum Pathol. 2008 May;39(5):731-9 [18329693.001]
  • [Cites] Exp Cell Res. 2008 Jul 1;314(11-12):2289-98 [18570923.001]
  • (PMID = 19226458.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Peptide Fragments; 0 / Procollagen; 0 / RNA, Messenger; 0 / Receptors, CXCR4; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / procollagen type I carboxy terminal peptide; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2652491
  •  go-up   go-down


80. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver.
  • METHODS: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery


81. Nowak D, Mazur AJ, Popow-Woźniak A, Radwańska A, Mannherz HG, Malicka-Błaszkiewicz M: Subcellular distribution and expression of cofilin and ezrin in human colon adenocarcinoma cell lines with different metastatic potential. Eur J Histochem; 2010;54(2):e14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcellular distribution and expression of cofilin and ezrin in human colon adenocarcinoma cell lines with different metastatic potential.
  • Four human colon adenocarcinoma cell lines - parental and three selected sublines, which differ in motility and metastatic potential, were used to investigate the expression level and subcellular localization of selected ABPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cell Biol. 2006 Aug;85(8):785-802 [16697076.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):71-9 [16538541.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1350-8 [17134718.001]
  • [Cites] Exp Cell Res. 2007 Apr 1;313(6):1106-20 [17292355.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):653-60 [16904765.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):642-52 [16926057.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):429-40 [17522712.001]
  • [Cites] Trends Biochem Sci. 2000 Jan;25(1):19-23 [10637608.001]
  • [Cites] Cancer Lett. 1999 Dec 1;147(1-2):31-8 [10660086.001]
  • [Cites] Glia. 2000 Nov;32(2):146-54 [11008214.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1785-93 [11106550.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):105-17 [11322830.001]
  • [Cites] Science. 2001 May 25;292(5521):1502-6 [11379633.001]
  • [Cites] Trends Cell Biol. 2001 Jul;11(7):288-93 [11413039.001]
  • [Cites] Mol Biotechnol. 2001 May;18(1):57-61 [11439699.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2442-9 [11581181.001]
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):104-9 [11792551.001]
  • [Cites] J Cell Sci. 2002 Jun 15;115(Pt 12):2569-80 [12045227.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Acta Biochim Pol. 2002;49(4):823-8 [12545189.001]
  • [Cites] Endothelium. 2002;9(4):247-61 [12572856.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):711-9 [12844144.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):R756-9 [14521851.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Science. 2004 Apr 30;304(5671):743-6 [15118165.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1890-909 [15203104.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):425-39 [15349817.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Sep 30;102(2):594-601 [6272804.001]
  • [Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):293-8 [1282514.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1605-12 [8183554.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31321-30 [8537403.001]
  • [Cites] J Biol Chem. 1996 Oct 18;271(42):26276-80 [8824278.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1307-22 [9087445.001]
  • [Cites] Folia Microbiol (Praha). 1998;43(5):507-10 [9821312.001]
  • [Cites] Trends Cell Biol. 1999 May;9(5):187-92 [10322453.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 10;258(2):395-400 [10329398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7300-5 [10377409.001]
  • [Cites] Science. 1999 Aug 6;285(5429):895-8 [10436159.001]
  • [Cites] J Cell Sci. 1999 Sep;112 Pt 18:3081-90 [10462524.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Dev Biol. 2005 Feb 1;278(1):231-41 [15649475.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R365-73 [15987432.001]
  • [Cites] Acta Biochim Pol. 2005;52(2):461-8 [15940343.001]
  • [Cites] Biochem Soc Trans. 2005 Nov;33(Pt 5):891-5 [16246005.001]
  • [Cites] Exp Mol Pathol. 2005 Dec;79(3):187-93 [16229833.001]
  • [Cites] Br J Dermatol. 2006 May;154 Suppl 1:11-5 [16712711.001]
  • [Cites] Mol Cell. 2006 Oct 6;24(1):13-23 [17018289.001]
  • (PMID = 20558337.001).
  • [ISSN] 2038-8306
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CFL1 protein, human; 0 / Cofilin 1; 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC3167302
  •  go-up   go-down


82. Matarrese P, Ascione B, Ciarlo L, Vona R, Leonetti C, Scarsella M, Mileo AM, Catricalà C, Paggi MG, Malorni W: Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol Cancer; 2010;9:207
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study.
  • BACKGROUND: Cathepsins represent a group of proteases involved in determining the metastatic potential of cancer cells.
  • Once released in the extracellular space, cathepsins contribute to metastatic potential by facilitating cell migration and invasiveness.
  • RESULTS: In the present work we first evaluated, by in vitro procedures, the role of cathepsins B, L and D, in the remodeling, spreading and invasiveness of eight different cell lines: four primary and four metastatic melanoma cell lines.
  • We found that i) cathepsin B, but not cathepsins L and D, was highly expressed at the surface of metastatic but not of primary melanoma cell lines and that ii) CA-074, or specific antibodies to cathepsin B, hindered metastatic cell spreading and dissemination, whereas neither chemical nor biological inhibitors of cathepsins D and L had significant effects.
  • CONCLUSIONS: These results suggest a reappraisal of the use of cathepsin B inhibitors (either chemical or biological) as innovative strategy in th